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Abstract 
 
The hepatitis B virus (HBV) remains a global health concern as chronic infection can lead to 
cirrhosis and hepatocellular carcinoma. Current therapies are only partially effective and do 
not target the HBV covalently closed circular DNA (cccDNA). cccDNA serves as a 
replication intermediate for the transcription of viral RNA, resulting in the persistence of 
infection. Several designer nucleases have therefore been developed to target cccDNA. Their 
mutagenic effect is mediated by causing double-strand breaks at target sites, consequently 
disrupting translation of viral proteins. Previous studies observed successful inhibition of 
HBV, with the use of homodimeric transcription activator-like effector nucleases (TALENs). 
TALENs are designed in pairs (left and right monomers) to cleave complementary strands of 
targeted DNA. They consist of a DNA-binding domain which is attached to the wildtype 
nuclease domain of FokI. TALENs have exhibited considerable predictable interaction with 
their target sites and have shown diminished toxicity in vitro and in vivo. Despite this success, 
TALENs containing wildtype FokI nuclease domains may be prone to off-target effects as 
two of the same domains (two left or two right) in close proximity on opposite strands of 
DNA can result in cleavage at unintended sites. To establish a more clinically applicable 
therapy, obligate heterodimeric TALENs targeted against the core (C) and surface (S) open 
reading frames (ORFs) of cccDNA were generated and referred to as C or S Variant 
TALENs. Variant TALENs contain mutant FokI nuclease domains. This allows for cleavage 
only when two different domains (one left and one right) are in close proximity on opposite 
strands of DNA thus reducing off-target effects. Overall the variant TALENs demonstrated 
significant knockdown of the HBV replication marker, hepatitis B surface antigen (HBsAg). 
Additionally variant TALEN-mediated targeted disruption occurred in ≥5.7% of total HBV 
DNA in vitro and ≥13% of total HBV DNA in vivo. Finally variant TALEN-treated mice also 
demonstrated significant knockdown of pregenomic RNA and surface mRNA levels as well 
as markedly reduced circulating viral particle equivalents. Together these results show that 
obligate heterodimeric TALENs are capable of HBV knockdown and serve as an advanced 
gene editing tool against chronic HBV infection. 
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Chapter 1 
1. Introduction 
1.1 Epidemiology of and infection by the hepatitis B virus 
 
The hepatitis B virus (HBV) belongs to the family Hepadnaviridae (Marion and Robinson, 
1983). HBV infects hepatocytes which can either lead to acute or chronic infection. Infected 
hepatocytes continuously shed virus into the bloodstream, making HBV highly infectious 
[reviewed in (Seeger and Mason, 2000)]. One of the first vaccination programmes against 
HBV took place in Taiwan as early as 1984 (D‐S et al., 1988). Chronic HBV infection 
remains a worldwide health concern despite universal vaccination that was implemented in 
1991, covering many hyperendemic areas (Meireles et al., 2015).  
To date HBV has been differentiated into 10 genotypes with A-H being well characterised 
and I-J being newly identified (Kramvis and Kew, 2007, Sunbul, 2014). Furthermore some 
genotypes are classified into sub-genotypes. The nucleotide difference between each genotype 
is approximately 8% whereas the nucleotide difference between sub-genotypes is between 4-
8% (McMahon, 2009). Epidemiological studies have revealed that genotypes and sub-
genotypes are geographically distributed (Kurbanov et al., 2010, Liaw et al., 2010, Croagh et 
al., 2015). The highest rates of infection occur in sub-Saharan Africa and Asia (Luo et al., 
2012). Genotypes A and E are predominantly found in sub-Saharan and western Africa 
respectively whereas Genotype D is mainly found in northern Africa (Kramvis and Kew, 
2007, Forbi et al., 2013). Genotypes B and C are found in Asia with genotype C being 
particularly widespread in South East Asia (Jutavijittum et al., 2008). It is important to 
distinguish between HBV genotypes as infection and disease progression differs significantly 
between them (Kiesslich et al., 2009). 
Infection in young children and adults differ quite notably as children are often more immune 
compromised compared to adults. In children younger than 1 year, infection is generally 
asymptomatic and almost always progresses to chronicity while most unvaccinated adults are 
capable of clearing acute infection (Liang, 2009, Seeger and Mason, 2000). In most cases, 
acute infection has an incubation period of about 2-3 months (Kappus and Sterling, 2013). In 
adults this incubation period is generally followed by a transient preicteric phase of symptoms 
such as nausea, anorexia, body aches and fatigue (McMahon et al., 1985, Liang, 2009, 
Kappus and Sterling, 2013). The preicteric phase is followed by jaundice which is often 
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cleared in a few weeks and acute liver failure occurs in as few as 1% of infected individuals 
(Bernal et al., 2010). 
The route of transmission differs between Asian and African populations due to the 
differences between the virus populations. Perinatal (vertical) transmission occurs mainly in 
Asia whereas horizontal transmission among young children occurs mainly in Africa (Mendy 
et al., 2010). In the case of vertical infections, mothers can transmit infection to their infant by 
percutaneous exposure during child birth. This demonstrates the highest rates of infectivity 
with a 90% chance of transmitting infection to the infant (Kelly, 2006, Yi et al., 2016). 
Chronic HBV infection is the major contributor to liver damage (Suhail et al., 2014). Many 
infected individuals will develop cirrhosis and/or hepatocellular carcinoma (HCC). The 
survival rate of chronically infected individuals depends on the severity of the disease. 
Currently 2.5 million people are chronically infected in South Africa alone. Furthermore it has 
been globally estimated that 1 million chronically infected individuals die annually (Spearman 
and Sonderup, 2014, Meireles et al., 2015). The effects of chronicity have been shown to 
differ between different HBV genotypes as well as host characteristics such as gender, where 
males are more likely to develop chronic infection (Yang et al., 2009). Chronic HBV infection 
remains a global concern which requires novel therapeutics to eradicate infection and disease. 
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1.2 HBV structure and replication 
 
HBV is an enveloped virus with a diameter of 42 nm. Viral particles exist as infectious (Dane) 
and non-infectious particles (Hruska et al., 1977). The Dane particle consists of viral surface 
antigens embedded within the lipid bilayer which surrounds an inner nucleocapsid. The 
nucleocapsid comprises the hepatitis B core antigen (HBcAg), the viral polymerase and the 
viral genome which is double-stranded relaxed circular DNA (rcDNA) (Dane et al., 1970). 
Non-infectious particles lack the nucleocapsid (Gavilanes et al., 1982). 
The virus replicates through an RNA intermediate, known as pregenomic RNA (pgRNA), 
yielding rcDNA. rcDNA comprises a full length minus strand and an incomplete plus strand 
(Rieger and Nassal, 1996, Seeger and Mason, 2000) (Figure 1.1). In the nucleus the rcDNA is 
repaired to covalently closed circular DNA (cccDNA) which serves as a template for the 
transcription of viral genes and plays an important role in HBV replication (Beck and Nassal, 
2007). 
The HBV genome is approximately 3.2 kilobase pairs in size, and encodes four overlapping 
open reading frames (ORFs) known as the surface (S), polymerase (P), precore/core (C) and 
X ORFs [reviewed in (Seeger and Mason, 2000)] (Figure 1.1). The S ORF is divided into 
three sections based on structure and functionality, namely Pre-S1, Pre-S2 and S. Pre-S1 
codes for the large (L) HBV surface antigen (HBsAg) while Pre-S2 mRNA codes for the 
middle (M) and small (S) HBsAgs (Churin et al., 2015). All surface proteins share the same C 
terminal domain and also contain a glycosylation site in the S domain. Additional 
modifications includes an N-linked oligosaccharide at the M domain as well as a myristic acid 
at the L domain (Lepère-Douard et al., 2009, Dandri and Locarnini, 2012). The L domain is 
responsible for viral entry as it is involved in attachment to hepatocytes. In the non-infectious 
virus there is very little to no L and M protein present but significantly more L protein is 
present in the Dane particles (Lamontagne et al., 2016).  
The C gene contains the precore as well as core regions (Jean-Jean et al., 1989). The S and C 
genes are similar in that they both comprise codons from which multiple in-frame translation 
takes place (Liang, 2009). This results in the production of structurally related but 
functionally different proteins. The C ORF encodes both the HBV e antigen (HBeAg) and the 
HBcAg. Transcription of the C ORF yields pgRNA as well as the precore RNA which is 
longer than the pgRNA at its 5’-end. Translation of the pgRNA from the core start site yields 
the HBcAg while translation of the precore RNA from the precore start site yields precore 
protein (Datta et al., 2012). The precore protein will ultimately be processed to HBeAg.  
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The function of the HBe protein is not well defined but it has been suggested to play a role in 
immune tolerance because it maintains persistent infection (Alexopoulou and Karayiannis, 
2014). The HBcAg is 185 amino acids in length. The first 149 amino acids are resilient to 
proteolytic cleavage and can therefore remain stable upon infection resulting in nucleocapsid 
assembly (Gallina et al., 1989, Hatton et al., 1992). The viral genome is surrounded by 240 
copies of the HBcAg which forms the viral capsid (Yu et al., 2013). Each HBcAg consists of 
four arginine-rich clusters at its C terminus, which contains nucleotide binding motifs capable 
of RNA binding (Hatton et al., 1992). 
The P ORF encodes viral polymerase which is the largest HBV protein, approximately 800 
amino acids in length (Bavand et al., 1989). Translation of the viral polymerase takes place 
from the second start codon of the pgRNA. The viral polymerase is composed of three 
domains, a terminal protein domain, a polymerase/reverse transcriptase domain and a 
ribonuclease H (RNase H) domain (Nassal, 2008, Hamadalnil and Bakheit, 2017). The 
terminal protein domain is involved with encapsidation as well as priming of the minus strand 
synthesis of the virus (Clark and Hu, 2015). The polymerase/reverse transcriptase domain acts 
as both an RNA-dependent DNA polymerase to make the minus strand from the pgRNA and 
a DNA-dependent DNA polymerase to initiate plus strand synthesis from the minus strand. 
The RNase H domain degrades the pgRNA once it has been reverse transcribed to the minus 
strand thereby allowing plus strand synthesis to begin.  
The X ORF encodes the hepatitis B virus X protein (HBx), which is important for HBV 
infection in vivo and is associated with hepatocarcinogenesis (Doria et al., 1995). Translation 
of HBx takes place from the HBx mRNA. Recently, HBx was found to target structural 
maintenance of chromosomes (Smc) complex Smc5/6 for ubiquitin-mediated degradation. 
Smc5/6 is a restrictive factor capable of suppressing the expression from episomal HBV DNA 
(Decorsière et al., 2016). 
The HBV genome also contains several functionally important cis-acting elements. These 
include three direct repeats, namely DR1, DR2 and DR1*, which play an important role in 
plus strand DNA synthesis (Habig and Loeb, 2006). Other elements such as enhancer 
elements, namely enhancer I (EnhI), located upstream of the X promoter, and enhancer II 
(EnhII), located upstream of the basic core promoter (BCP), are responsible for liver specific 
viral gene expression (Doitsh and Shaul, 2004).  
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EnhI has been shown to play an extremely important role in HBV transcription. In the 
absence of EnhI in HBV transgenic mice, viral gene expression is low which results in 
inadequate virion production (Guidotti et al., 1995). EnhII, in addition to regulating its own 
transcription, has been shown to regulate the transcription of the Pre-S1 and Pre-S2 promoters 
(Yuh and Ting, 1990). The need for two enhancer elements suggests that HBV gene 
expression is regulated temporally (Doitsh and Shaul, 2004). EnhI is activated relatively early 
upon infection, followed by EnhII activation associated with simultaneous EnhI silencing 
(Doitsh and Shaul, 2004). Temporal gene expression is a characteristic of DNA viruses. In the 
case of HBV these elements control the expression of different HBV genes with respect to the 
viral replication cycle which expresses early and late genes (Doitsh and Shaul, 2004). Several 
other elements such as glucocorticoid-responsive element (GRE) located within the S ORF, 
polyadenylation signal within the C ORF and a post-transcriptional regulatory element 
overlapping EnhI and the HBx ORF have all been shown to play important roles in HBV gene 
expression (Tur-Kaspa et al., 1988). 
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Figure 1.1: The HBV genome. 
The rcDNA is shown at the centre of the genome which has a partially double-stranded plus and minus strand. The genome is approximately 3.2 kb in 
length comprising four overlapping open reading frames depicted by Surface (S), Polymerase (P), Precore/Core (C) and X. The Enhancer I and II 
elements are located directly upstream of the X promoter and basic core promoter respectively. A polyadenylation signal is on the plus strand within 
the core ORF. Nucleotide co-ordinates are read in the order from the unique EcoRI site within the genome [Adapted from (Seeger and Mason, 2015)]. 
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HBV replication is initiated upon infecting hepatocytes. HBV surface proteins play an 
important role in cell entry (Figure 1.2). Glycosaminoglycan-mediated clustering of viral 
particles results on the surface of hepatocytes (Ely et al., 2016). This is important for entry as 
the virions enter the cell through the interaction of the myristoylated L HBsAg with the 
sodium taurocholate co-transporting polypeptide (NTCP). This interaction was only 
discovered recently (Yan et al., 2012). 
Host factors may play a role in viral attachment and uptake of virions into cells (Glebe and 
Urban, 2007, Rehman et al., 2015). The binding of the virus to the receptor becomes 
irreversible (Dandri and Petersen, 2016). Internalisation mechanisms have been partly 
described for several genotypes (Schmitz et al., 2010). Briefly, once the virus enters the cell, 
the nucleocapsid (rcDNA surrounded by the capsid) is released into the cytoplasm. The 
nucleocapsid accumulates at the nuclear membrane of the cell where it can interact with the 
nuclear pore complex. The nucleocapsid is subsequently released into the nucleus, where it 
disassembles (Kann et al., 2007).  
Upon disassembly of the nucleocapsid repair of the rcDNA is initiated. The viral polymerase 
is covalently attached to the 5’ end of the minus strand and needs to be removed before repair 
can be completed. Removal of the polymerase is mediated by host machinery and plus strand 
synthesis is completed thus forming cccDNA (Beck and Nassal, 2007). cccDNA becomes 
associated with histone and non-histone proteins where it resides in the cell as a 
minichromosome (Newbold et al., 1995). HBV viral transcripts are unspliced and 
polyadenylated from a single common polyadenylation signal and capped at the 5’ end 
(Schreiner and Nassal, 2017).  
Virion assembly is initiated when the viral polymerase interacts with a cis-acting element, 
epsilon (Ɛ), on the 5’ end of the pgRNA to initiate encapsidation (Hu and Boyer, 2006). 
Reverse transcription is initiated through protein priming whereby the first nucleotide is 
covalently attached to a tyrosine residue within the terminal protein domain of the viral 
polymerase. Initially a 3-4 nucleotide (nt) sequence is reverse transcribed which will serve as 
a primer for minus strand synthesis. The pgRNA contains 3 direct repeats DR1, DR2 and 
DR1*. At its 5’ end it has DR1 and at its 3’ end it has DR2 and DR1*. The viral polymerase 
translocates to the 3’-end of the pgRNA where the 3-4 nt primer binds to DR1*. Reverse 
transcription of the pgRNA proceeds to produce the minus strand of the viral genome.  
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Only part of DR1* is reverse transcribed so the minus strand will have DR1 at its 3’ end and 
DR2 and the partial DR1* at its 5’ end. The RNase H activity of the viral polymerase will 
degrade most of the pgRNA only leaving behind a small RNA sequence that will serve as the 
primer for plus strand synthesis. The RNA primer covers DR1 and as a consequence is also 
complementary to DR2 at the 5’-end of the pgRNA allowing it to be moved to DR2. This is 
referred to as primer translocation (Habig and Loeb, 2006, Wang et al., 2014). Plus strand 
synthesis can then begin and will extend from DR2 to the partial DR1*. At this point the plus 
strand switches from using the partial DR1* as template to using DR1. The minus strand has 
to circularise to bring its 3’-end close to its 5’-end and allow template switching to occur. 
Synthesis continues to form the incomplete plus strand. This results in newly synthesised 
rcDNA. 
Surface protein synthesis takes place on the surface of the endoplasmic reticulum (ER) and 
once the surface proteins are translated they will embed themselves in the ER membrane. The 
nucleocapsid buds into the ER and gains a lipid bilayer with the already embedded surface 
proteins thus forming the mature virion which is secreted into the extracellular milieu. 
Alternatively the mature nucleocapsid can be recycled to the nucleus to produce cccDNA 
(Mhamdi et al., 2007). 
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Figure 1.2: The HBV replication cycle. 
1.) The virion attaches to the cell surface through glycosaminoglycan-mediated clustering of viral particles on the surface of hepatocytes whereby surface 
proteins recognise and binds to the NTCP receptor. 2.) Once in the cell the nucleocapsid enters the nucleus where disassembly occurs to release the rcDNA 
genome. 3.) The capsid disassembles and the viral genome is repaired to cccDNA. 4.) cccDNA serves as a template for the transcription of viral RNAs. 5.) 
The viral RNAs are then translated into proteins in the cytoplasm. Once translated, the viral polymerase binds to the pgRNA, initiating encapsidation to yield 
the nucleocapsid. 6.) The pgRNA will then be reverse transcribed. Reverse transcription leads to minus strand synthesis followed by plus strand synthesis 
leading to rcDNA. 7.) This newly synthesised capsid can either obtain viral envelope proteins in the endoplasmic reticulum after which it exits the cell ready 
to infect another cell or 8.) re-enter the nucleus to produce more cccDNA [Adapted from (Liu et al., 2013)]. 
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1.2.1 cccDNA persistence 
The exact mechanism of partially double-stranded circular DNA conversion to cccDNA is 
still unclear (Cai et al., 2012). Briefly, cccDNA formation requires the removal of covalently 
attached viral polymerase from the 5’ end of the minus strand. This results in a protein-free 
rcDNA (PF-rcDNA) intermediate, capable of persisting in infected cells [reviewed in (Seeger 
and Mason, 2000)]. cccDNA formation also requires the removal of the RNA primer at the 5’ 
end of the plus strand. Finally the repair of the plus strand by cellular replicative machinery 
followed by the subsequent ligation of the DNA results in cccDNA (Levrero et al., 2009).     
cccDNA rarely integrates into the host genome and therefore exists as an episomal 
minichromosome in the nucleus, however in the event of such integration, HBV DNA 
sequences are generally truncated (Ozkal-Baydin, 2014). Because cccDNA exists as a 
minichromosome it becomes undetectable to host immune responses (Allweiss and Dandri, 
2017). Furthermore, cccDNA is continuously formed, either from incoming virions or newly 
synthesised nucleocapsid upon cell entry [reviewed in (Chang et al., 2014)] (Figure 1.2). Once 
cccDNA is established in the nucleus it is regulated by two enhancer elements, EnhI and 
EnhII as well as four promoters, namely the basic core promoter (BCP) and pre-S1, pre-S2 
and X promoters (Levrero et al., 2009). These rely on the co-operation of transcription factors 
as well as signalling factors such as co-activators and co-repressors. 
cccDNA is robust and owes its minimal sequence plasticity to the four overlapping ORFs of 
the HBV genome. Partially double-stranded circular DNA to cccDNA conversion has been 
detected in vitro within 48 hours of infection and each infected hepatocyte has been found to 
contain 1-50 copies of cccDNA (Zhang et al., 2003, Guo et al., 2016). Chronic infection is a 
result of persistence of the cccDNA. In addition, cccDNA remains relatively stable in 
quiescent hepatocytes. The exceptionally resilient and replicative properties of cccDNA have 
made it exceedingly difficult to eradicate. Therefore the need for a curative therapy that 
disables cccDNA is highly sought after. 
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1.3 Current anti-HBV treatment 
 
Currently vaccination against HBV is the leading strategy to prevent infection. The active 
ingredient in the hepatitis b vaccine is the HBsAg. Anti-HBs antibodies are used as a 
replicative marker of HBV and therefore determine immunity against the virus. The first 
vaccinations contained HBsAg purified from the plasma of chronically infected patients, 
however these vaccinations have been replaced by recombinant vaccines which became 
available in the early 1980s to increase the safety and immunogenicity of the vaccine 
(Szmuness et al., 1980, Thomssen et al., 1982). Importantly antibody response occurs in 
>90% of the population and in addition, stimulates a long-term immune response (Liao et al., 
1999). Protection against HBV is defined as an anti-HBs titre >10 IU/L whereas individuals 
with titres <10 IU/L are defined as “non-responders” (Wiedmann et al., 2000). Factors such as 
age, obesity, type I diabetes or smoking can result in non-responsiveness (Andy et al., 2006). 
Despite these regimes, vaccination remains ineffective against already established infection.  
There are currently two main therapeutic strategies that have been approved by the U.S Food 
and Drug Administration (FDA) for treating chronic HBV infection (De Clercq et al., 2010). 
The first strategy consists of nucleoside/nucleotide analogues (NAs) where the nucleoside 
compounds are lamivudine, entecavir and telbivudine and the nucleotide compounds are 
adefovir dipivoxil and Tenofovir disoproxil (Fung et al., 2011). The second strategy consists 
of immune-based therapy such as interferon-α (IFN-α) [reviewed in (Jordheim et al., 2013)]. 
The NAs function primarily by inhibiting HBV DNA polymerase activity thus suppressing 
replication (Karayiannis, 2012). Oral NAs have become the favoured option of treatment 
against chronic infection for two reasons. Firstly they have been found to efficiently suppress 
replication and secondly, the oral method of administration makes it easier for compliance 
(Fung et al., 2011). The human immunodeficiency virus (HIV) is known to be highly 
mutagenic and exceedingly susceptible to drug resistance. Combinatorial therapy such as 
highly active antiretroviral therapy (HAART) has therefore become well established against 
HIV. The rationale behind combinatorial therapy was consequently adopted for combating 
HBV infection by combining different NA treatments. However in the case of chronic HBV, 
combinatorial therapy is yet to show any additional benefits against viral replication (Fung et 
al., 2011). 
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IFN-α functions as an anti-proliferative and antiviral immunoregulator (Maher et al., 2008) 
and can have its half-life extended with PEGylation (PEG-IFN-α) (Dozier and Distefano, 
2015). IFN-α binds to specific receptors on the cell surface which results in a signalling 
cascade that regulates the transcription of genes that are involved in viral replication 
inhibition [reviewed in (Platanias, 2005)]. PEG-IFN-α treatment has been shown to decrease 
HBsAg with minimal drug resistance however treatment is very inefficient as only 30% of 
patients respond.  
New drugs have been developed to target viral components such as MCC-478 which is a 
derivative of adefovir. MCC-478 functions by inhibiting protein priming. As mentioned 
before, the viral polymerase must bind to ε to initiate protein priming and signal encapsidation 
of pgRNA. The inhibition of protein priming therefore prevents the encapsidation of pgRNA 
thus reducing viral replication. This drug seems promising against lamivudine resistant 
mutants [reviewed in (Kang et al., 2015)]. 
As the entry receptor for HBV, the NTCP has become a promising therapeutic target. 
Myrcludex-B is a synthetic lipopetide, derived from the pre-S1 domain (Volz et al., 2013). 
The pre-S1 domain has been shown to be important for cell entry as it interacts with NTCP to 
enter the cell. Myrcludex-B has shown specific binding to NTCP, inhibiting its function and 
furthermore it has shown a reduction in HBV binding and intrahepatic viral entry (Nakabori et 
al., 2016). 
Although there has been some success in viral synthesis inhibition with the use of these 
antiviral treatments, viral elimination was not established and current drugs have little or no 
effect on HBV cccDNA (Werle–Lapostolle et al., 2004). Therefore a new approach against 
cccDNA is needed. 
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1.4 Designer nucleases 
 
While available treatment options for chronic HBV sufferers are aimed at curing infection and 
alleviating disease progression, they have no effect on established cccDNA pools (Revill and 
Locarnini, 2016). This has led researchers to the use of a class of genome editing tools 
referred to as designer nucleases. Research on genetic engineering began over half a century 
ago when it was discovered that bacteria and yeast were capable of using homologous 
recombination to replace DNA sequences within their genomes (Weeks et al., 2016). Since 
then scientists have been driven to study and develop novel gene editing tools. These tools 
have gained popularity as they can be designed to target any known sequence. 
In recent years designer nucleases have taken precedence in the field of gene therapy. The 
ability to design a custom-made gene editing tool targeted to any known sequence has made 
the use of designer nucleases exceptionally attractive. Various designer nucleases have been 
used for studying complex diseases as well as inducing mutagenic effects to cure or alleviate 
the burden of disease (Amer, 2014). Some of the first successful uses of designer nucleases 
have been observed in human embryonic stem cells (hESCs), induced pluripotent stem cells 
(iPSCs) as well as in model organisms such as zebrafish, rats and plants (Hockemeyer et al., 
2009, Merkert and Martin, 2016). 
Designer nucleases have been developed to mutate cccDNA (Bloom et al., 2013, Weber et al., 
2014, Kennedy et al., 2015). In general, their mutagenic effect is mediated by causing double 
strand breaks (DSBs) at target sites (Lee et al., 2016b). Nucleases are designed to cause DSBs 
and this stimulates error-prone repair mechanisms at target sites. The two main pathways used 
to repair DSBs in eukaryotes are the homology directed repair (HDR) and the non-
homologous end joining (NHEJ) repair pathways [reviewed in (Lieber, 2010)]. 
DSBs are in fact a normal occurrence in eukaryotic cells. Once a DSB is detected, the cell will 
depend on NHEJ for repair. NHEJ occurs faster and more frequently than HDR (Mao et al., 
2008). The rate-limiting step in HDR is that it requires undamaged homologous DNA as a 
template for repair (Zaboikin et al., 2017). In the case of HBV, the NHEJ repair mechanism is 
favoured because it is more efficient at knocking out cccDNA. Following induction of DSBs 
by nucleases, the NHEJ repair mechanism restores the DNA sequence. However after 
repeated target cleavage, NHEJ repair leads to insertion and deletion mutations (indels) which 
disables cccDNA, consequently disrupting viral gene expression. The most widely used 
nucleases used to target the HBV ORFs have been zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and RNA-guided nucleases [i.e. the clustered 
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regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) or the 
CRISPR/Cas9 system] (Cradick et al., 2010, Bloom et al., 2013, Lin et al., 2014). 
1.4.1 ZFNs and CRISPR/Cas9 structure 
 
ZFNs were among the first gene editing tools developed and later tested in animal models 
(Kim et al., 1996, Provasi et al., 2012). Naturally, zinc fingers are DNA-binding proteins that 
play an important role in gene regulation, in particular, regulating transcriptional activation. 
Initially discovered in the early 1980s, zinc fingers showed a novel principle of DNA 
recognition (Miller et al., 1985). Other DNA binding proteins relied on the two-fold 
symmetry of the double helix DNA structure for DNA recognition, whereas zinc fingers are 
linearly linked for DNA recognition [reviewed in (Klug, 2010)]. One of the first applications 
in studying zinc fingers showed that the fusion of zinc finger peptides to bind DNA can 
selectively repress or activate domains thus regulating gene expression (Miller et al., 1985). 
Zinc fingers are best characterised by the Cysteine2-histidine2 (Cys2-His2) fold, which has 
the following sequence, X2-Cys-X2,4-Cys-X12-His-X3,4,5-His, where X represents any amino 
acid and the distance between the cysteine and histidine residues are variable (Miller et al., 
1985). Each zinc finger consists of a short antiparallel β-sheet containing two cysteine 
residues and an α-helix containing two histidine residues that is held together by a zinc ion, 
hence the name zinc finger. In the event of DNA recognition, three fingers wrap around the 
DNA, whereby the α-helices interact with three nucleotides within the major groove of DNA 
(Elrod-Erickson et al., 1996). Engineered zinc finger proteins are typically made up of three 
zinc fingers and consequently bind to 9 basepair (bp) DNA sequences. By attaching a zinc 
finger DNA-binding domain to the nuclease domain of FokI, an artificial nuclease capable of 
binding and cleaving targeted DNA is created. 
Unlike ZFNs where protein domains recognise target DNA, the CRISPR/Cas9 system uses 
both RNA and protein to target DNA. The CRISPR/Cas9 system was the most recent tool to 
have been added to the repertoire of gene editing technologies. The CRISPR/Cas system was 
first discovered in Archaea, and later shown to also exist in Eubacteria (Jinek et al., 2012). 
The CRISPR/Cas system exhibited an intelligent immune response against invading 
bacteriophages (Barrangou et al., 2007, Jinek et al., 2012). Upon infection, the bacteriophage 
DNA is processed. This DNA is incorporated into the archaeal or bacterial genome at a region 
termed as the CRISPR locus. This equips the bacterium with an acquired immune response 
against future bacteriophage invasion.  
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In the natural system, transcripts from the CRISPR locus are processed into CRISPR RNAs 
(crRNAs) and transactivating CRISPR RNA (tracrRNAs) responsible for guiding the CRISPR 
associated (Cas) nuclease to complementary DNA sequence for cleavage (Wu et al., 2014). 
Cas proteins have been differentiated into two classes subdivided into 6 types based on 
differences in cleavage efficiency [reviewed in (Mohanraju et al., 2016)]. For the purpose of 
gene editing the crRNAs and tracrRNAs were fused to produce small guide RNAs (sgRNAs) 
(Jinek et al., 2012). The sgRNAs complex with a class II, type II Cas nuclease 9 from 
Streptococcus pyogenes referred to as Cas9 which gives rise to the complete CRISPR/Cas9 
system (Shmakov et al., 2015). In the event of target sequence recognition, a protospacer 
adjacent motif (PAM) sequence upstream from the target sequence will direct Cas9 cleavage 
to result in desired mutagenic effects (Sander and Joung, 2014). 
1.4.2 TALEN structure and design 
 
Transcription activator like effectors (TALEs) were first discovered in the Xanthomonas 
genus of bacteria [reviewed in (Boch and Bonas, 2010)]. These bacteria infect crop plants 
which have devastating effects on agriculture and so motivated the study of TALEs. The 
molecular mechanisms of these bacteria revealed that effector proteins were secreted  into the 
cells of host organisms (Nemudryi et al., 2014). Upon further investigation it was found that 
effector proteins bind to DNA and act as transcription factors, hence the name “transcription 
activator-like effector”. 
TALE proteins comprise three domains namely a central domain necessary for DNA binding, 
a gene transcription activation domain, and a nuclear localisation signal (Moore et al., 2014). 
The DNA binding properties of TALEs presented a potentially useful tool to engineer 
artificial nucleases. However propagating TALE sequences presented a challenge in terms of 
cloning repeat arrays (Gaj et al., 2013). This hampered the use of TALENs for a long time, 
but several methods have now been developed to rapidly assemble custom TALE arrays. 
These techniques include restriction enzyme and ligation methods (Morbitzer et al., 2011), the 
Golden Gate method (Cermak et al., 2011) and the fast ligation based automatable solid phase 
high-throughput (FLASH) method (Reyon et al., 2012).  
Naturally occurring TALEs contain as few as 1.5 to 33.5 tandem repeats (Moscou and 
Bogdanove, 2009). For the purpose of gene editing TALEs are normally composed of 17.5 or 
18.5 tandem repeats comprising 34 highly conserved amino acids (Deng et al., 2014) (Figure 
1.3). The C-terminal repeat that binds to a nucleotide at its 3’-end only consists of 20 amino 
acids and this is referred to as a half-repeat (Zhang et al., 2014).  
Chapter 1-Introduction 
16 
 
Positions 12 and 13 are referred to as the repeat variable diresidues (RVDs) which are 
responsible for single nucleotide recognition (Jankele and Svoboda, 2014).  
Researchers deciphered the RVD code necessary to engineer specific DNA binding arrays, 
which was an important advance for TALEN design (Boch et al., 2009). Amino acids NG, 
NN, HD and NI bind to nucleotides T, G, C and A respectively. However some degeneracy 
occurs in the code as NN may also bind A. Researchers then explored increasing code 
specificity and it was observed that replacing NN with NH or NK increases specific binding 
to G (Cong et al., 2012). With the TALE code deciphered, custom-designed TALEs were 
attached to a nuclease domain for site-specific cleavage. To test this theory, the DNA binding 
domain of the TALE was placed into a vector that was previously used for producing ZFNs 
(Christian et al., 2010). This generated TALEs which contained the FokI nuclease domain, 
giving rise to TALENs. 
The FokI endonuclease is only functional as a dimer and as a consequence TALENs are 
designed as two monomers that come together on target DNA to create a DSB. TALE DNA-
binding domains bind one strand of the DNA helix necessitating a design where each TALEN 
monomer binds to opposite strands of DNA in a manner that leaves a 12-25 bp spacer region 
(Yan et al., 2013). Upon binding target DNA the FokI nuclease domains of each monomer 
dimerise, cleaving the DNA backbone resulting in DSBs. One limitation of engineering 
TALEs is that the target sequence should start with a thymine base for optimal TALE 
interaction with DNA (Rogers et al., 2015). This limitation can however be overcome by 
designing TALENs with different spacer sequence lengths to ensure that the target sequence 
starts with a thymine (Booher and Bogdanove, 2014). 
TALENs are more specific than ZFNs because single nucleotide recognition occurs as 
opposed to triple nucleotide recognition. This also makes TALENs more “flexible” to 
engineer against target sites. Importantly ZFs do not function independently of each other as 
the α-helix of one finger influences the orientation of the α-helix side chains in an adjacent 
finger. This complicates ZFN design, whereas TALENs do not have the problem of 
influencing neighbouring monomers. Studies have shown that nucleases result in successful 
inactivation of HBV replication, however each nuclease differs in specificity and efficacy 
(Bloom et al., 2013, Weber et al., 2014, Kennedy et al., 2015). 
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Figure 1.3: TALE structure and RVD nucleotide base recognition. 
TALEs are usually comprised of 17.5 or 18.5 tandem repeats that bind to target DNA through its RVDs. The degenerate RVD code appears in 
the top right corner. One repeat consists of 34 amino acids with positions 12 and 13 being the RVD outlined as HD. FokI nuclease domains are 
depicted as ovals and they cleave at non-specific sequences (N12-25) [Adapted from (Kim and Kim, 2014)]. 
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1.5 Designer nucleases targeted against the HBV genome 
1.5.1 ZFNs and CRISPR/Cas9 used to target HBV genome 
 
ZFNs were the first engineered nucleases used for the targeted disruption of HBV, however 
while viral DNA sequences were effectively targeted there was no evidence of an effect on 
cccDNA (Cradick et al., 2010). A more recent study used self-complementary adeno-
associated virus (AAV)  mediated delivery of ZFNs to improve antiviral activity, but  ZF 
pairs proved to be inefficient and one pair was cytotoxic in HepAD38 cells (Weber et al., 
2014). While the CRISPR/Cas9 system has achieved much acclaim, a study using these RNA-
guided nucleases exhibited only 5% targeted mutagenesis in cccDNA (Fu et al., 2013).  ZFNs 
and CRISPR/Cas9 have recently shown some promise as designer nucleases; however they 
have largely been associated with off-target effects (Pattanayak et al., 2011, Lee et al., 2016a). 
Assembly of zinc finger domains that are capable of binding extended stretches of DNA with 
high affinity has proven to be challenging (Ramirez et al., 2008). Although individual zinc 
fingers can easily bind to nucleotide triplets, the position of each finger within the domain can 
reduce binding affinity. Several studies using ZFNs for genome editing has exhibited off-
target cleavage and substantial genotoxicity (Beumer et al., 2006). CRISPR/Cas9 is highly 
active even with imperfectly matched RNA-DNA interfaces in human cells as sgRNA can 
tolerate a number of mutations and this leads to off-target effects. A recent study identified 
potential off-targets which were mutagenised with frequencies higher than those observed at 
the intended on-target site (Fu et al., 2013).  
1.5.2 TALENs targeted against the HBV genome 
 
The first study to describe the use of TALENs against HBV demonstrated successful 
inhibition of the virus (Bloom et al., 2013). Four TALENs were designed to target S, P and C 
genes. Huh7 and HepG2.2.15 liver-derived cells were treated with S and C TALEN plasmids. 
Concentrations of HBsAg secreted by the cells into the culture supernatant were significantly 
decreased when treated with S TALENs and approximately 35% targeted mutagenesis was 
observed in cccDNA. In vivo experiments carried out in mice also revealed significantly 
decreased serum HBsAg and intrahepatic HBcAg levels when using the S and C TALENs 
respectively. Furthermore between 58-87% mutagenesis in HBV target plasmids was 
observed in mice.   
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Another study, designed TALENs to target regions around the RNase H domain of the viral 
polymerase as well as two sets of TALENs targeted against the C gene (Chen et al., 2014). 
Huh7 cells were co-transfected with TALEN plasmids targeted against the P and C ORF as 
well as the pCR.HBV.A.EcoRI HBV replication competent plasmid. This study demonstrated 
significant reductions in HBeAg as well as HBsAg both in vitro and in vivo. Furthermore, 
32% targeted mutagenesis in cccDNA molecules was observed in Huh7 cells when using 
TALENs targeted against the HBV C ORF.  
Taken together these experiments demonstrate that TALENs are active against HBV 
replication, exhibiting considerable predictable interaction with their target sites and have 
shown diminished toxicity in vitro and in vivo (Bloom et al., 2013, Miller et al., 2015). 
Despite the recent success with TALENs capable of cutting cccDNA, homodimeric FokI 
nuclease domains may be prone to off-target effects (Grau et al., 2013). 
1.6 Heterodimeric TALEN design 
 
The specificity of TALEN technology is crucial to the success as a therapy. Targeted cleavage 
occurs when left (L) and right (R) monomers bind to DNA. However cleavage can still occur 
when homodimers (two L or two R monomers) bind non-specifically to DNA resulting in 
cleavage at unintended sites (Miller et al., 2007). To reduce off-target effects caused by 
cleavage at unintended sites, Miller and colleagues focused on generating FokI variants that 
were more specific to site-directed cleavage. Miller et al designed a 4 cycle-step-wise 
mutational system to select variants with the least off-target effects (Miller et al., 2007). These 
variants retained their catalytic activity upon mutation. Importantly during each cycle of 
variant design, amino acid substitutions that were generated in one cleavage domain (L or R) 
were unmodified at that same position for the partner monomer. Modelling was based on 
published FokI structures (Wah et al., 1997). The 4 cycle-step-wise mutational system led to 
Q486E and I499A substitutions in the left monomer as well as E490K and I538V in the right 
monomer (Miller et al., 2007). The Q486E variant interacts with E490K while the I499A 
variant interacts with I538V (Miller et al., 2007). The effects of these associations are 
described in Table 1.1. 
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Table 1.1: The interactions between the left and right monomers of FokI heterodimeric variants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left monomer variants Right monomer variants Interaction between left and right monomers 
Q486E 
 
E490K Glutamic acid (E) is negatively charged whereas lysine (K) 
is positively charged, electrostatic interaction will occur 
between a left and a right monomer, however amino acid 
490 on the left monomer is an E, so electrostatic repulsion 
will occur between two left monomers 
I499A 
 
I538V Alanine (A) and valine (V) are hydrophobic, and therefore 
reduce hybridisation energy between L and R monomers. 
To strengthen the interaction, monomers will only 
hybridise after binding to intended target sequences 
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The 4 cycle-step-wise mutational system ultimately gave rise to obligate heterodimeric 
nucleases which also comprise L and R monomers. The mutations in the monomers of 
obligate heterodimeric nucleases disrupt dimerisation between homodimers while promoting 
dimerisation between heterodimers thus reducing off-target effects (Figure 1.4).  
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Figure 1.4: Obligate heterodimeric design improves TALEN specificity and reduces off-
target cleavage. 
A-C indicates wild type FokI nuclease domains. A indicates heterodimeric TALENs where 
double-arrow lines show DNA cleavage. B and C indicate homodimeric TALENs where 
double-arrow lines show off-target DNA cleavage. D-F indicates mutated FokI nuclease 
domains. D indicates heterodimeric TALENs where double-arrow lines show DNA cleavage. 
E and F indicate homodimeric TALENs where crosses show that homodimerisation is 
inhibited and cleavage does not occur. Target DNA is only cleaved when L and R monomers 
come together. Two of the same monomers result in electrostatic repulsion and do not cleave.
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1.7 Aim 
 
The aim of this study was to generate obligate heterodimeric TALENs by replacing the 
homodimeric FokI nuclease domains of existing well-characterised anti-HBV TALENs with 
heterodimeric FokI nuclease domains. The obligate heterodimeric TALENs were designed to 
target the S and C ORFs of HBV (Figure 1.5). The focus was on improving specificity of 
cccDNA cleavage and subsequently inactivating HBV viral replication. Surface protein 
inhibition, transcriptional repression, targeted mutagenesis and cytotoxicity were 
characterised in in vitro and in vivo models.  
 
Figure 1.5: Obligate heterodimeric TALEN binding sites. 
Two obligate heterodimeric TALENs were generated to target the C and S ORFs of the HBV 
cccDNA as depicted by arrows at sites illustrated in parentheses. Additionally the C and S 
TALENs also target the overlapping P ORF [Adapted from (Bloom et al., 2013)]. 
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Chapter 2 
2. Materials and Methods 
2.1 Plasmids 
2.1.1 pCH-9/3091 
 
Established by Nassal and colleagues, pCH-9/3091 was designed as an HBV replication 
competent plasmid (Nassal et al., 1990). This plasmid comprises a full-length HBV sequence 
with terminal repeats that allows for the transcription of a greater-than-genome length pgRNA 
(imitating what would normally be transcribed from cccDNA). Furthermore the reverse 
transcription of pgRNA results in cccDNA formation. pCH-9/3091 is based on genotype D 
and transcription of the pgRNA is under the control of a cytomegalovirus immediate-early 
(CMV-IE) promoter. It was used in this study to mimic HBV replication both in vitro and in 
vivo. 
2.1.2 pCI-neo eGFP 
 
This is an enhanced green fluorescent protein (eGFP) reporter which is under the control of 
the CMV-IE promoter, generated by Passman and colleagues (Walter et al., 2000). pCI-neo 
eGFP served as an in vitro reporter useful for monitoring transfection efficiencies. Higher 
GFP expression correlates with greater transfection efficiency. 
2.1.3 pCI-neo FLuc 
 
This is a Firefly luciferase plasmid which served as an in vivo reporter used for monitoring 
hepatic delivery efficiency (Ely and Arbuthnot, 2010). Firefly luciferase oxygenates luciferin 
to oxyluciferin which is highly unstable and when it returns to its ground state it gives off 
energy in the form of light (von Degenfeld et al., 2009). 
2.1.4 pUC118 
 
This is a bacteriophage packaging plasmid. It is a high copy plasmid and does not contain any 
TALE nor HBV sequences thus serving as a mock control in all experiments to ensure that 
there is uniform DNA quantity in each transfection (Mussolino et al., 2014). 
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2.1.5 Anti-HBV TALEN plasmids 
 
TALEs were derived from the TALE protein AvrBs4 scaffold (Mussolino et al., 2011), and 
were designed to target the C and S ORFs of the HBV genome (Bloom et al., 2013). TALE 
repeat arrays were generated by Golden Gate cloning. The amino acid sequences for the 
TALE DBDs and DNA base recognition are shown in Tables 2.1 and 2.2. The CMV promoter 
drives expression of the left and right TALEN monomers. Each TALE monomer comprises 
the haemagglutinin (HA) epitope followed by a nuclear localisation signal (NLS), a TALE 
DNA-binding domain (DBD) and finally the wildtype FokI nuclease domain (Hus et al., 
2004, Lange et al., 2007). This resulted in pVAX CMV TALEN plasmids and for simplicity 
these plasmids have been referred to as pCMV CL TALEN (WT), pCMV CR TALEN (WT), 
pCMV SL TALEN (WT) and pCMV SR TALEN (WT) (Table 2.3). 
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Table 2.1: The TALEN DBD and DNA base recognition sequences for core TALEs (from 2319-2370 bp relative to the HBV genome) 
 
Core TALEs 
Left TALE DBD sequence DNA base Right TALE DBD sequence DNA base 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG 
T 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG 
T 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG 
T 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG 
T 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
G 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG 
G 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG 
T 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
A 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG 
C 
LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG 
G 
Chapter 2-Materials and methods 
27 
 
Table 2.2: The TALEN DBD and DNA base recognition sequences for surface TALEs (from 411-462 bp relative to the HBV genome) 
Surface TALEs 
Left TALE DBD sequence DNA base Right TALE DBD sequence DNA base 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG 
 
A 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C 
LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G 
LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T 
LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G 
LTPEQVVAIASHDGGKQALETVQALLPVLCQAHG C LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A LTPDQVVAIASNIGGKQALETVQRLLPVLCQAHG A 
LIPQQVVAIASNGGGKQALETVQRLLPVLCQDHG T LTPEQVVAIASNKGGKQALETVQRLLPVLCQAHG G 
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2.2 Generation of obligate heterodimeric TALEN plasmids 
 
The pCMV TALEN (WT) plasmids and plasmids encoding heterodimeric FokI nuclease 
domains (pAC AAVS1 Left and pAC AAVS1 Right) were used to generate obligate 
heterodimeric TALENs. All heterodimeric TALEN nomenclature is described in Table 2.3. 
The left heterodimeric FokI nuclease domain contained the Q486E and I499A mutations 
whereas the right heterodimeric FokI nuclease domain contained the E490K and I538V 
mutations (Miller et al., 2007). 
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Table 2.3: TALEN plasmid nomenclature 
TALEN description Plasmid nomenclature Plasmid Description 
TALENs containing wildtype FokI 
nuclease domain sequence 
 
 
pCMV CL TALEN (WT)  Core left TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the 
wildtype FokI nuclease domain sequence 
pCMV CR TALEN (WT)  Core right TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the 
wildtype FokI nuclease domain sequence 
pCMV SL TALEN (WT)  Surface left TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the 
wildtype FokI nuclease domain sequence 
pCMV SR TALEN (WT)  Surface right TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the 
wildtype FokI nuclease domain sequence 
TALENs containing variant  FokI 
nuclease domain sequence (obligate 
heterodimeric FokI) 
 
pCMV CL TALEN (Var)  Core left TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the variant 
left FokI nuclease domain sequence  
pCMV CR TALEN (Var)  Core right TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the variant 
right FokI nuclease domain sequence 
pCMV SL TALEN (Var)  Surface left TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the variant 
left FokI nuclease domain sequence 
pCMV SR TALEN (Var)  Surface right TALE with upstream nuclear localisation signal (NLS), 
haemagglutinin (HA) epitope, CMV promoter attached to the variant 
right FokI nuclease domain sequence 
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2.2.1 Preparation of TALE- and nuclease-encoding DNA fragments for ligation 
 
To generate obligate heterodimeric TALEN plasmids, all four pCMV TALEN (WT) plasmids 
and plasmids encoding heterodimeric FokI nuclease domains were cleaved with ApaI and 
BamHI restriction enzymes (Figure 2.1). All restriction digest reactions were carried out 
according to the manufacturer’s instructions (Thermo Scientific, CA, USA). Briefly, the 
digest was carried out in a 20 µL reaction containing 1 μg of plasmid DNA, 1 U of ApaI 
followed by 1 U of BamHI, 2µL of a 10× Buffer BamHI and dH2O up to 20 μL. The reaction 
was incubated at 37 °C for two hours. The restriction digests were subsequently resolved on a 
1% agarose gel containing 0.3 μg/mL of ethidium bromide (Appendix 5.1.1). The gel was 
then viewed with a G:Box UV transilluminator (Syngene, Cambridge, UK) and the 5 284 bp 
bands (Appendix 5.1.2 and 5.1.3) were excised and purified  using the QIAquick® Gel 
Extraction Kit (Qiagen, Hilden, Germany) (Appendix 5.1.5). The purity and concentration of 
the extracted DNA was determined by spectrophotometry. The plasmids encoding 
heterodimeric FokI nuclease domains were digested as above and the 601 bp bands (Appendix 
5.1.2 and 5.1.3) were excised then purified. 
2.2.2 Ligation of variant nuclease domain-encoding fragments into anti-HBV TALE 
backbones 
 
The TALE backbone fragments from pCMV TALEN (WT) plasmids and the insert fragments 
from either pAC AAVS1 Left variant or pAC AAVS1 Right FokI nuclease-encoding 
plasmids were ligated and cloned to produce the final obligate heterodimeric TALEN 
plasmids, referred to as pCMV CL TALEN (Var), pCMV CR TALEN (Var), pCMV SL 
TALEN (Var), pCMV SR TALEN (Var) (Table 2.3). The ligation took place overnight at 
14 °C with 1 U of T4 Ligase, 2 µL of 10× Ligation buffer and dH2O up to 20 μL, according to 
the manufacturer’s instructions (Thermo Scientific, CA, USA) (Appendix 5.1.6). In addition, 
negative controls containing TALE backbones without nuclease domain-encoding fragments 
were also ligated as mentioned above. 
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Figure 2.1: Generation of obligate heterodimeric TALENs. 
1. pAC AAVS1 Left variant contains the sequence for the left obligate heterodimeric FokI 
nuclease domain and this sequence was cleaved by ApaI and BamHI restriction enzymes. 
pCMV TALEN (WT) contains the sequences for the left TALEs (either core or surface). The 
wildtype FokI nuclease domain sequence was removed by ApaI and BamHI restriction and 
then discarded. 2. Products after cleavage. 3. The left heterodimeric FokI nuclease domain 
sequence was inserted into the vector containing the left TALE (either core or surface). The 
same steps (1-3) were used to generate the right obligate heterodimeric FokI TALEN. pAC 
AAVS1 Right variant containing the sequence for the right obligate heterodimeric FokI 
nuclease domain and pCMV TALEN (WT) containing the right TALEs were used.  
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2.2.3 Cloning of ligated products and subsequent positive clone selection 
 
After the overnight incubation, 10 µL of each ligation reaction was used to transform 100 µL 
of chemically competent Escherichia coli (Appendix 5.1.7). In addition the negative controls 
(TALE backbone fragments without the insert) were transformed into E. coli. Single colonies 
from the overnight culture were picked and inoculated into 10 mL of Luria Bertani medium 
supplemented with kanamycin (40 µg/mL) which was left to incubate at 37 °C overnight with 
shaking. Plasmid DNA was extracted and purified from E. coli using Econospin™ All-in-One 
Mini Spin Columns according to the manufacturer’s instructions (Epoch Life Science, TX, 
USA) (Appendix 5.1.8). The purity and concentration of DNA was determined using 
spectrophotometry. The clones were screened alongside pCMV TALEN (WT) plasmids using 
EcoRI and DraI to distinguish between the wildtype and variant plasmids, clones were also 
screened alongside pCMV TALEN (WT) plasmids with BglI to determine TALE DBD 
patterns. Finally clones were screened with PdiI to distinguish between the left and right 
variant FokI domain sequences and their amino acid sequence alignment data is illustrated in 
Appendix 5.1.4. 
2.3 Bulk plasmid preparation 
 
All positive clones were prepared using the QIAGEN Plasmid Maxi Kit according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany).  DNA was eluted in 100 μL of water 
and stored at -20 °C (Appendix 5.1.9). 
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2.4 In vitro characterisation of heterodimeric TALENs 
2.4.1 Culture conditions for liver and kidney derived cells 
 
Human hepatoma 7 (Huh7) and HepG2.2.15 cells were used to assess TALEN efficacy in 
vitro. Huh7 cells were cultured in a CellStar® 75cm
2
 flask (Greiner Bio-One, Frickenhausen, 
Germany) using low glucose (1 g/L) Gibco™ Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Thermo Scientific, CA, USA),  supplemented with penicillin (100 000 U/mL), 10% 
foetal bovine serum (FBS) and streptomycin (100 μg/mL). Cells were incubated at 37 °C and 
5% CO2 until they reached a confluency of 80-90% which was observed under a light 
microscope (Olympus CKX31,Tokyo, Japan).  
Upon reaching confluency approximately 50% of medium was removed and discarded while 
the remaining medium was removed and placed in a 50 mL tube with an equal volume of 
fresh medium. This mixture was filter sterilised and served as conditioned medium (CM). 
Cells were washed with 5 mL of saline containing 1× EDTA followed by a 5 minute 
incubation at 37 °C in 10 mL of saline. The saline was removed and the cells were treated 
with 3 mL of 1× TrypLE Express (Thermo Scientific, CA, USA) for 3 minutes to allow for 
cellular detachment. The flask was gently tapped and this was sufficient to dislodge the cells 
from the surface of the flask. Once the cells were in suspension, 7 mL of fresh low glucose 
medium was added and resuspended in the flask. The cell suspension was transferred to a 50 
mL tube and centrifuged at 200 ×g for 3 minutes. The resulting pellet was resuspended in 1 
mL of fresh low glucose medium and transferred to a new flask containing 14 mL of CM. 
These cells were incubated at 37°C and 5% CO2 until the next passage. 
HepG2.2.15 cells were cultured similarly to Huh7 cells. HepG2.2.15 cells were grown in a 
CellStar® 75cm
2
 flask using high glucose (4.5 g/L) Gibco™ DMEM (Thermo Scientific, CA, 
USA), supplemented with penicillin (100 000 U/mL), 10% foetal bovine serum (FBS) and 
streptomycin (100 μg/mL). Upon reaching confluency, these cells were subjected to the same 
procedures as above; however the pellet was resuspended in normal glucose medium and then 
was transferred to a new flask containing 14 mL of fresh normal glucose medium only. Cells 
were maintained as above until the next passage.  
Human embryonic kidney 293 (HEK293) cells were grown in the same medium and 
incubation conditions as HepG2.2.15 cells. Briefly, upon reaching confluency, cells were 
incubated with 10 mL of saline containing 1× EDTA for 3 minutes at 37 °C. At this point 
saline was carefully removed and 10 mL of fresh medium was added and used to resuspend 
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the cells. This suspension was transferred to a 50 mL tube and centrifuged at 200 ×g for 4 
minutes. The pellet was resuspended in 1 mL of fresh medium and transferred to a new flask 
containing 14 mL of fresh medium. Cells were maintained as in the case of Huh7 cells until 
the next passage. 
All cells were regularly tested for mycoplasma contamination using the MycoAlert™ 
Mycoplasma Detection kit (Lonza, Basel, Switzerland) (Appendix 5.2.1). 
2.4.2 Immunofluorescence microscopy 
 
Huh7 cells were seeded in a 96-well plate at a density of 50% in 90 µL of medium per well, 
one day prior to transfection. Lipofectamine™ 3000 was used to transfect 100 ng of all 
TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] according to the 
manufacturer’s instructions (Thermo Scientific, CA, USA) (Appendix 5.2.2). In addition, 100 
ng of pUC118 was transfected which served as a negative control and 100 ng of pCI-neo 
eGFP was transfected to assess transfection efficiency. These transfections were all carried 
out in triplicate and assessed for expression by immunofluorescence 48 hours after 
transfection. 
Forty eight hours after transfection, the transfection efficiency was assessed by analysing GFP 
expression in Huh7 cells. Expression was monitored using a fluorescence microscope 
(Axiovert 100M, Zeiss, Germany) with the fluorescein isothiocyanate (FITC) filter. 
Following detection of GFP expression, medium was discarded from the wells and cells were 
washed with 100 µL of 1× phosphate buffered saline (PBS) (Thermo Scientific, CA, USA) 
(Appendix 5.2.3). The PBS was removed and cells were fixed in 100 µL of 4% 
paraformaldehyde (PFA) (Appendix 5.2.3) by incubating at room temperature for 15 minutes. 
The PFA was carefully removed and cells were washed twice with 100 μL of 1× PBS. The 
PBS was removed and cells were permeabilised in 100 μL of 0.1% Triton-X (Sigma-Aldrich, 
MO, USA) (Appendix 5.2.3) and incubated at room temperature for 10 minutes. Triton-X was 
removed and cells were washed twice in 100 µL of 1× PBS. The cells were blocked in 50 µL 
of 1% bovine serum albumin (BSA) (Roche Applied Science, Mannheim, Germany) 
(Appendix 5.2.3) for 1 hour in a humidity chamber.  
Following the 1 hour incubation, BSA was removed and cells were incubated with 15 µL of 
mouse anti-HA primary antibody (diluted 1:200 in 1% BSA) for 1 hour in a humidity 
chamber. Cells were washed twice with 100 μL of 1× PBS and incubated with 15 μL of goat 
anti-mouse, Alexa flour 488 labelled secondary antibody (diluted 1:200 in 1% BSA) for 40 
minutes in a humidity chamber. Cells were again washed twice in 100 μL 1× PBS, PBS was 
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removed and cells were incubated in 25 μL of 1×4,6-diamidine-2-phenylindole chloride 
(DAPI) (Appendix 5.2.3) at room temperature for 10 minutes. Cells were finally washed 
twice in 100 μL of 1× PBS and imaged by fluorescence microscopy under the FITC and 
DAPI filters. 
2.4.3 HBsAg enzyme-linked immunosorbent assays (ELISA) 
 
Huh7 cells were seeded in a 6-well plate at a cell density of 50% in 1750 μL of medium per 
well one day prior to transfection. Lipofectamine™ 3000 was used to co-transfect 300 ng of 
pCH-9/3091, 200 ng of pCI-neo eGFP and 1000 ng of each of the left and right TALEN 
plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or 2000 ng of pUC118 as a 
mock control. All transfections were performed according to the manufacturer’s instructions, 
carried out in triplicate and assessed for HBsAg expression 48 hours after transfection. 
Forty eight hours after transfection, the transfection efficiency was first assessed by analysing 
GFP expression using the fluorescence microscope (Appendix 5.2.4). Following detection of 
GFP expression, HBsAg expression was measured by an enzyme-linked immunosorbent 
assay (ELISA) using the Monolisa™ HBs Ag ULTRA kit (Bio-Rad, CA, USA). Briefly 100 
µL of culture supernatant was added to a well of the provided microplate coated with 
monoclonal anti-HBsAg antibodies. Fifty microlitres of conjugate solution was added to the 
supernatant, mixed and incubated for 1.5 hours at 37 °C. After incubation the wells were 
washed five times with 1× washing solution using the ImmunoWash™ 1575 Microplate 
Washer (Bio-Rad, CA,USA). Thereafter 100 µL of enzyme development solution was added 
into each well. The microplate was incubated in the dark at room temperature for 30 minutes 
after which the reaction was stopped by adding 100 µL of stopping solution into each well. 
The optical density of each sample was read 4 minutes later at 490 nm and 655 nm using an 
iMARK™ Microplate reader (Bio-Rad, CA, USA). The OD reading at 655 nm was subtracted 
from the OD reading at 490 nm.  
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2.4.4 In vitro celI endonuclease assay 
 
HepG2.2.15 cells were seeded in a 6-well plate at a cell density of 50% in 1750 µL of 
medium per well one day prior to transfection (Day 0). Lipofectamine™ 3000 was used to co-
transfect 200 ng of pCI-neo eGFP and 1000 ng of the left and right TALEN plasmids [either 
pCMV TALEN (WT) or pCMV TALEN (Var)] or 2000 ng of pUC118 as a mock control 
(Day 1). All transfections were carried out in triplicate according to the manufacturer’s 
instructions. All transfection efficiencies were assessed by analysing GFP expression using 
the fluorescence microscope (Appendix 5.2.5). Seventy two hours after transfection (Day 3) 
cells were washed and spent media was replaced. One hundred and twenty hours after 
transfection (Day 5) the cells were dissociated and 20% reseeded per well of a 6-well plate. 
The remaining 80% was stored in 1 mL of 1× PBS at -70 °C. This process (seeding, 
transfection and reseeding) was repeated twice (Figure 2.2). Cells from the final transfection 
were harvested and used to assess targeted cleavage. 
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Figure 2.2: HepG2.2.15 transfections for the CelI assay. 
Cells were seeded at a density of 50% on Day 0 and transfected with 200 ng pCI-neo eGFP and 1000 ng of the left and right TALEN plasmid 
[either pCMV TALEN (WT) or pCMV TALEN (Var)] or 2000 ng of pUC118 as a mock control on day 1. On Day 3 the wells were washed and 
2000 μL of fresh medium was added. On Day 5 cells were re-seeded at a 1:5 ratio where the remaining cells were stored in 1 mL of 1% PBS at    
-70°C. This process was carried out 3 times in total. 
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Total DNA was extracted from HepG2.2.15 cells using the QIAamp DNA Mini Kit according 
to the manufacturer’s Blood and Body Fluids Spin protocol (Qiagen, Hilden, Germany). 
Briefly, 20 µL of QIAGEN Protease was mixed with 200 µL of cell suspension followed by 
adding 200 µL of buffer AL and pulse vortexing for 15 seconds. This mixture was incubated 
at 56°C for 10 minutes after which 200 µL of 100% ethanol was added and the mixture pulse-
vortexed for 15 seconds. The mixture was transferred to a QIAamp Spin Column and 
centrifuged at 6000×gfor 1 minute. The flow-through was discarded and 500 µL of buffer 
AW1 was added to the column and centrifuged as above. The flow-through was discarded and 
500 µL of buffer AW2 was added to the column centrifuged at maximum speed in a benchtop 
centrifuge for 3 minutes. Additionally the flow-through was discarded and the columns were 
centrifuged for an extra minute to remove any residual wash buffer. The collection tube 
containing the flow-through was discarded and the column was transferred into a clean 
microcentrifuge tube. Total DNA was eluted by adding 30 µL of dH2O to the column, 
incubating at room temperature for 1 minute and centrifuging at 6000× g for 1 minute. 
The sequences spanning approximately 260 bp upstream and 260 bp downstream of the 
predicted target sites for the C and S TALENs were amplified by PCR. Wildtype and mutant 
HBx PCR amplicons mixed in a 1:1 ratio served as the positive control for the CelI assay. 
Sequences amplified from pUC118 treatment were used as a negative control. The amplicons 
(~520 bp) were amplified and subjected to heteroduplex formation. The PCR was set up as 
follows, 12.5 µL of 2× Ready Mix (KAPA HiFi HotStart Ready Mix PCR Kit), 10 pmol of 
each respective forward and reverse primers (Table 2.4), 5 µL of extracted DNA and 5.5 µL 
of dH2O. The reaction was carried out with the Bio-Rad T100™ Thermal Cycler under the 
following conditions: initial denaturation at 95 °C for 15 seconds, annealing at 60 °C for 15 
seconds, extension at 72 °C for 15 seconds, final elongation at 72 °C for 5 minutes and 
cooling to 4 °C. PCR products were resolved on a 1.5% agarose gel containing 0.3 μg/mL of 
ethidium bromide (Appendix 5.1.1) and imaged with a G:Box UV transilluminator (Syngene, 
Cambridge, UK). The PCR products were purified using the QIAquick® Gel Extraction Kit 
and eluted in 30 µL of dH2O (Appendix 5.1.5). The purity and concentration of DNA was 
determined by spectrophotometry. 
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Table 2.4: Primer sequences used to amplify putative TALE binding and cleavage sites 
for C and S ORFs 
 
Primer name Primer sequence 
Core forward 5’-GAACTAATGACTCTAGCTACCT-3’ 
Core reverse 5’-CCTACAAACTGTTCACATTT-3’ 
Surface forward 5’-CCTAGGACCCCTTTCTCGTGT-3’ 
Surface reverse 5’-ACTGAGCCAGGAGAAACGGG-3’ 
 
The CelI assay was set up as follows: 300 ng of PCR product, 2 µL of 10× NEB buffer 2 
(New England Biolabs, NJ, USA) and dH2O to a final volume of 12 µL. The reaction was 
carried out under the following conditions: initial denaturation at 95 °C followed by cooling 
to 35 °C at a ramp rate of -0.1 °C/s and holding at 35 °C for 2 minutes. At this point the 
samples were removed and incubated on ice for 5 minutes. One microlitre of CelI enzyme 
was added to the samples while 1 µL of dH2O was added to the negative control (Appendix 
5.2.7). Samples were returned the thermocycler and held at 4 °C for 10 minutes followed by 
heating to and incubating at 37 °C for 25 minutes. The samples were left to cool to 4 °C and 
remained at 4 °C for an additional 10 minutes. Cleaved products were resolved by agarose gel 
electrophoresis. Image J software was used to measure band intensities and targeted 
disruption was calculated as previously described (Guschin et al., 2010) (Appendix 5.2.8). 
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2.4.5 Cell viability assay 
 
HEK293 cells were seeded in a 96-well plate at a cell density of 30% in 112.5 μL of medium 
per well 6 hours prior to transfection. Polyethylenimine (PEI) (0.1 mg/mL) was used to co-
transfect 15 ng of pCH-9/3091, 15 ng of pCI-neo eGFP and 85 ng of the left and right 
TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or 170 ng of 
pUC118 as a mock control. Furthermore 50% dimethyl sulphoxide (DMSO) was used to 
transfect cells and served as a positive control. These transfections were all carried out in 
triplicate and assessed for cell viability 48 hours after transfection. 
Forty eight hours after transfection, the transfection efficiency was assessed by analysing GFP 
expression using fluorescence microscopy (Appendix 5.2.9). Following detection of GFP, 20 
μL of MTT (5 mg/mL dissolved in 1× PBS) (Sigma-Aldrich, MO, USA) was added into each 
well and incubated at 37 °C for 1 hour. After incubation culture medium was removed and 
200 µL of DMSO was added and resuspended in each well. This was left to incubate for 5 
minutes after which optical densities were measured at 570 nm and 655 nm using an 
iMARK™ Microplate reader (Bio-Rad, CA, USA). The OD reading at 655 nm was subtracted 
from the OD reading at 570 nm.   
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2.5 In vivo characterisation of heterodimeric TALENs 
2.5.1 Hydrodynamic injection of NMRI mice with TALEN-expressing plasmids 
 
TALEN-mediated silencing of viral replication was assessed in the hydrodynamic injection 
(HDI) mouse model of HBV replication. The injection creates hydrodynamic pressure 
generated by a rapid injection of a large volume of solution into the tail veins of mice which 
induces immediate congestion in the heart (Budker et al., 1996, Bonamassa et al., 2011). This 
causes the solution to accumulate in the inferior vena cava therefore creating intravascular 
pressure in the venous system. The solution then refluxes into the liver via the hepatic vein. 
The force carried by the pressurised solution enlarges the liver and permeabilises the plasma 
membrane to allow for delivery into the parenchyma hepatocytes. Injections were performed 
in the tail veins of 3-5 week old Naval Medical Research Institute (NMRI) mice, weighing 
between 20-30 g. All experiments conducted on NMRI mice were according to procedures 
approved by the University of the Witwatersrand Animal Ethics Screening Committee 
(Appendix 5.3.1). The mice were categorised into 5 groups, namely the mock group (n=7), 
the SWT group (n=7), the CWT group (n=5), the S Variant group (n=6) and the C Variant 
group (n=5). The injectates contained 30 µg of plasmid DNA and comprised 10% of the body 
weight of each mouse (Kovacsics and Raper, 2014). All plasmids were prepared using the 
Endo-Free Plasmid Maxi kit according to the manufacturer’s instructions (Qiagen, Hilden, 
Germany) (Appendix 5.3.2).  
Briefly, a solution of 5 µg of pCH-9/3091, 10 µg of each right and left TALEN plasmids 
[either pCMV TALEN (WT) or pCMV TALEN (Var)] or 20 µg of pUC118 as well as 5 µg of 
pCI-neo FLuc (luciferase reporter gene plasmid) were injected into mice. The pCI-neo FLuc 
plasmid was used to assess hepatic delivery. The mice were injected on day 0 and blood 
samples were collected on days 3 and 5 to measure HBV replication markers [(HBsAg and 
circulating viral particle equivalents (VPEs)] and to assess liver toxicity by measuring ALT. 
Immediately after collection the blood was allowed to clot at 4 °C for 1 hour prior to 
processing. The blood samples were subsequently centrifuged at 6000 ×g for 10 minutes to 
separate serum from whole blood.  Furthermore, mice were euthanised on day 5 by CO2 
exposure and their livers were harvested to assess the effects of TALENs on HBV gene 
expression and site-directed targeted cleavage. Although the experiment is transient, the 
effects of TALEN cleavage will be permanent and therefore justify its potential as an 
effective therapy. 
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2.5.2 Bioluminescence imaging 
 
To confirm efficient delivery of plasmids, bioluminescence imaging was performed on day 3 
after HDI using an IVIS Kinetic In Vivo Optical Imaging System (Perkin Elmer Inc., MA, 
USA). Briefly, mice were intraperitoneally injected with 150 mg/kg of a 15 mg/mL D-
luciferin solution (Perkin Elmer Inc., MA, USA) and placed in an induction chamber. Five 
percent isoflurane (anaesthetic) was pumped directly into the induction chamber and once the 
mice were unconscious they were immediately transferred to the imaging chamber with an 
anaesthetic mask delivering 2% isoflurane. Mice were imaged and returned to their cages. 
2.5.3 ELISA 
 
ELISAs were carried out on day 3 and 5 serum samples to determine HBsAg knockdown. The 
serum was carefully collected and diluted at a 1:4 ratio with saline and 100 µL used for the 
assay. The ELISA was carried out as described in Section 2.4.3. 
2.5.4 Quantification of HBV VPEs 
 
Real-time quantitative PCR (qPCR) was used to determine the amount of VPEs from serum 
of injected mice. The remaining serum from day 3 and 5 was carefully collected and diluted in 
a 1:8 ratio in saline. Total DNA was extracted using the QIAamp DNA Mini Kit as described 
in Section 2.4.4. Extracted DNA was used as the template for qPCR. 
The AcroMetrix™ HBV Panel 1.2 mL (Thermo Scientific, CA, USA) was used to generate a 
standard curve. The qPCR was set up with the FastStart Essential DNA Green Master (Roche 
Applied Science, Mannheim, Germany) as follows: 10 µL of 2× Master mix, 10 pmol each of 
the HBV surface forward and reverse primers (Table 2.5), 5 µL of template DNA and 3 µL  
of nuclease-free water were mixed.  
Table 2.5: Primer sequences used to amplify the HBV surface gene 
 
Primer name Primer sequence 
HBV Surface forward 5’-TGCACCTGTATTCCCATC-3’ 
HBV Surface reverse 5’-CTGAAAGCCAAACAGTGG-3’ 
 
The qPCR reaction was carried out with the Bio-Rad CFX96™ Real Time System under the 
following cycling conditions: initial denaturation at 95 °C for 10 minutes followed by 40 
cycles of denaturing at 95 °C for 20 seconds, annealing at 57 °C for 20 seconds and extension 
at 72 °C for 20 seconds with a single SYBR® Green signal acquisition at this step. For the 
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melting curve analysis DNA was denatured at 95 °C for 10 seconds followed by annealing at 
65 °C for 5 minutes and then heating to 95 °C at a ramp rate of 0.1 °C/s with continuous 
SYBR® Green signal acquisition. 
2.5.5 Assessing HBV gene expression 
 
To assess HBV gene expression total RNA was extracted from 100 mg of mouse liver. The 
liver sections were homogenised in 1 mL of TRIzol® Reagent (Thermo Scientific, CA, USA) 
and incubated at room temperature for 5 minutes. The samples were centrifuged at10 000 ×g 
for 10 minutes at 4 °C to collect cellular debris, and the homogenates transferred to clean 
microcentrifuge tubes. Two hundred microlitres of chloroform was added to the homogenates 
followed by vigorous shaking for 15 seconds. This mixture was incubated at room 
temperature for 3 minutes and then centrifuged at 12 000 ×g for 15 minutes at 4 °C. At this 
point the mixture was separated into the organic phase (containing proteins), the interphase 
(containing DNA) and the upper aqueous phase (containing RNA). Approximately 500 µL of 
the aqueous phase was carefully transferred to clean microcentrifuge tubes. Thereafter 500 µL 
of isopropanol was added to the aqueous phase and gently mixed by inversion. This mixture 
was incubated at room temperature for 10 minutes and centrifuged at 12 000 ×g for 10 
minutes at 4 °C. The resulting supernatant was removed and the pellet was washed in 1 mL of 
75% ethanol followed by centrifugation at 7 500 ×g for 5 minutes at 4 °C. The pellet was 
resuspended in 200 µL of nuclease free water. The purity and concentration of RNA was 
determined by spectrophotometry. 
The extracted RNA was reverse transcribed using the QuantiTect reverse transcription kit 
(Qiagen, Hilden, Germany). Briefly, the extracted RNA was initially treated to remove any 
genomic DNA (gDNA) contamination. The clearance of gDNA was set up as follows: 1 µg of 
RNA, 2 µL of 7× gDNA Wipeout buffer and RNase-free water up to 14 µL were mixed. This 
reaction was incubated at 42 °C for 8 minutes. The RNA was reverse transcribed to cDNA as 
follows: 14 µL treated RNA, 4 µL 5× QuantiTect reverse transcription buffer, 1 µL of 
QuantiTect reverse transcription primer mix and 1 µL of QuantiTect reverse transcription 
enzyme were mixed. The reaction was incubated at 42 °C for 30 minutes followed by heat 
inactivation at 95 °C for 3 minutes. The resulting cDNA was stored at -20 °C. 
HBV surface mRNA and pgRNA were quantified relative to murine glyceraldehyde-3-
phosphate dehydrogenase (mGAPDH) mRNA. Previous studies have shown that mGAPDH 
levels were not affected by transfections (Bloom et al., 2013, Chen et al., 2014). The qPCR 
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mixes were prepared and carried out as described in Section 2.5.4. Surface primers are 
indicated in Table 2.5 whereas core and mGAPDH primers are indicated in Table 2.6. 
Table 2.6: Primer sequences used to amplify HBV and mGAPDH genes 
 
Primer name Primer sequence 
HBV Core forward 5’-ACCACCAAATGCCCCTAT-3’ 
HBV Core reverse 5’-TTCTGCGAGGCGGCGA-3’ 
mGAPDH forward 5’-TTCACCACCATGGAGAAGG-3’ 
mGAPDH reverse 5’-GGCTGGACTGTGGTCATGA-3’ 
 
HBV gene expression was normalised to that of mGAPDH expression. Relative amounts were 
determined from Ct values. 
2.5.6 Assessment of in vivo targeted cleavage 
 
To assess targeted cleavage in murine samples, 25 mg of liver was dissected, homogenised 
and stored in 80 µL of 1× PBS. Total DNA was extracted with the QIAamp DNA Mini Kit 
(Tissue protocol). Briefly, 20 µL of QIAGEN Protease was added and resuspended in the 
lysate. This mixture was incubated at 56 °C for 4 hours until the liver was completely lysed. 
Four microlitres of RNase A (100 mg/mL) was added to the mixture and pulse vortexed for 
15 seconds followed by incubating at room temperature for 2 minutes. Two hundred 
microlitres of AL buffer was added to the mixture, pulse vortexed for 15 seconds and 
incubated at 70 °C or 10 minutes. Two hundred microlitres of 100% ethanol was added to the 
mixture and pulse vortexed for 15 seconds. The mixture was transferred to a QIAamp Spin 
Column and centrifuged at 6000 ×g for 1 minute. The flow-through was discarded and 500 
µL of buffer AW1 was added to the column and centrifuged as above. The flow-through was 
discarded and 500 µL of buffer AW2 was added to the column and centrifuged at maximum 
speed for 3 minutes. Once again the flow-through was discarded and the column was 
centrifuged at maximum speed for an extra minute to remove any residual wash buffer. Total 
DNA was eluted by adding 30 µL of dH2O to the column, incubating at room temperature for 
1 minute and centrifuging at 6000 ×g for 1 minute. The CelI assay was performed as 
described in Section 2.4.4. PCR products were resolved on a 1.5% agarose gel containing 0.3 
μg/mL of ethidium bromide (Appendix 5.3.3). PCR products not treated with CelI served as 
an additional negative control (Appendix 5.3.4). 
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2.5.7 Assessing liver toxicity 
 
Alanine aminotransferase (ALT) activity, which is indicative of liver damage, was measured 
at the National Health Laboratory Services (NHLS) at the Charlotte Maxeke Johannesburg 
Academic Hospital using an automated photometric analyser (Roche Diagnostics, Rotkrenz, 
Switzerland). 
2.6 Data analysis 
 
For the statistical analysis, the mean and standard error of the mean (SEM) were calculated 
and plotted for each data set. The statistical difference was determined by performing a Two-
tailed Student’s t test using GraphPad Prism 4.0 (GraphPad Software Inc., CA, USA). Only 
groups with p <0.05 were considered to be significant. 
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Chapter 3 
3 Results 
3.1 Successful generation of obligate heterodimeric TALEN vectors 
 
Two anti-HBV TALENs were re-engineered as obligate heterodimers to improve specificity 
of target cleavage and subsequently inhibition of viral replication. These heterodimeric 
TALEN sequences comprise DBDs, which have been specifically designed to target 
sequences within the C and S ORFs of HBV, and left or right variant FokI nuclease domains 
for targeted cleavage (See Methods, Figure 2.1). The pUC118 plasmid that does not contain 
any TALE sequences was used as a negative control in all experiments. The obligate 
heterodimeric TALEN vectors were generated by replacing the wildtype FokI nuclease 
domain-encoding sequences from the pCMV TALEN (WT) vectors with variant FokI 
nuclease domain-encoding sequences from the pAC-AAVS1 plasmids, using standard 
molecular cloning techniques (Section 2.2) (Appendix 5.1.3). 
This gave rise to pCMV CLTALEN (Var), pCMV CRTALEN (Var), pCMV SLTALEN 
(Var) and pCMV SRTALEN (Var) plasmids. Clones were screened to differentiate between 
pCMV TALEN (WT) and pCMV TALEN (Var) plasmids, to ensure that the correct DBDs 
were present in each TALEN and finally to discriminate between the left and the right 
obligate heterodimeric FokI nuclease domain-encoding sequences. 
To differentiate between WT and Variant TALENs, EcoRI and DraI restriction enzymes were 
used. EcoRI cuts WT TALENs once and Variant TALENs twice whereas DraI cuts WT 
TALENs thrice and Variant TALENs twice (Figure 3.1.1). In addition, BglI restriction digests 
were performed to confirm that Variant TALENs contain the same DBD patterns as the WT 
(Figure 3.1.2). A final restriction digest was performed with PdiI. This enzyme was used to 
differentiate between the left and right FokI Variant sequences as PdiI cuts the left Variant 
twice and the right Variant thrice (Figure 3.1.3). In accordance with the plasmid maps, 
sequencing alignment data and agarose gels, all clones presented the correct banding patterns 
(Appendix 5.1.2-5.1.4) (Figures 3.1.1-3.1.3). 
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Figure 3.1.1: Verification of WT and Variant TALEN assembly. 
The Variant TALENs were produced by removing the FokI nuclease domain DNA sequence from existing pCMV TALEN plasmids and 
replacing it with either the left or right variant FokI nuclease domain sequences from the pAC-AAVS1 plasmids. (a) The vector maps indicating 
the selected restriction digest enzymes are shown. (b) One percent agarose gel electrophoresis confirmed banding patterns for pCMV TALEN 
(WT) plasmids with EcoRI producing a 5885 bp band and DraI producing 4279, 1428 as well as 178 bp bands. Banding patterns for pCMV 
TALEN (Var) plasmids were also correct with EcoRI producing 5633 and 252 bp bands while DraI produced 4457 and 1428 bp bands. (MWM: 
molecular weight marker, O’GeneRuler 1 kb DNA Ladder, Thermo Scientific, CA, USA). 
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Figure 3.1.2: Verification of TALEN DNA binding domain (DBD)-encoding sequences. 
The pCMV TALEN (WT) and pCMV TALEN (Var) contain the same DBDs. BglI produces 
distinct banding patterns of the DBDs for both (WT) and (Var) TALENs. One percent agarose 
gel electrophoresis confirmed that pCMV TALEN (Var) plasmids produced the same banding 
patterns as pCMV TALEN (WT) plasmids. (MWM: molecular weight marker, O’GeneRuler 
1 kb DNA Ladder, Thermo Scientific, CA, USA). 
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Figure 3.1.3: Verification of vectors carrying Variant nuclease domain sequences. 
To distinguish between left and right nuclease domain sequences of the pCMV TALEN (Var) plasmids, PdiI restriction digestion was performed. 
(a) Vector maps indicating the selected restriction digest enzyme are shown. (b) One percent agarose gel electrophoresis confirmed banding 
patterns for the left variant nucleases which produced 3630 and 2255 bp bands, whereas the right variant nucleases produced 2511, 2225 and 
1119 bp bands. (MWM: molecular weight marker, O’GeneRuler 1 kb DNA Ladder, Thermo Scientific, CA, USA). 
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3.2 Obligate heterodimeric TALENs are efficiently expressed in liver-
derived cells 
 
The WT and the Variant TALENs contain an HA epitope that is useful for detecting in vitro 
and in vivo expression. To confirm TALEN expression in liver-derived cells, Huh7 cells were 
transiently transfected with left or right TALEN plasmids [either pCMV TALEN (WT) or 
pCMV TALEN (Var)] or with the pUC118 plasmid which does not contain an HA epitope 
and was used as a negative control. In a separate transfection cells were transfected with pCI-
neo eGFP as a control to assess transfection efficiency. Immunofluorescence was assessed by 
staining transfected cells with anti-HA primary antibody followed by staining with 
fluorescently labelled secondary antibody.  
GFP expression was detected in the control cells (Figure 3.2). This suggests that transfection 
of Huh7 cells with plasmids expressing TALEN monomers were also successful. 
Immunofluorescence staining for the TALEN monomers produced a blue signal from DAPI 
staining as well as a green signal resulting from detection of the HA epitope in the cytoplasm 
and nuclei of cells (Figure 3.2). Cells transfected with pUC118 only produced a blue signal 
from DAPI staining and did not produce green signal. These results demonstrate the 
expression of each TALEN monomer in liver-derived cells.  
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Figure 3.2: Immunofluorescence detection of TALEN monomers in Huh7 cells. 
Huh7 cells were transiently transfected with left or right TALEN monomers to determine TALEN expression in cultured cells. Cells were 
transfected with GFP to determine transfection efficiency and also transfected with a mock plasmid (pUC118). An anti-HA primary antibody 
followed by fluorescently labelled secondary antibody was used to detect the HA epitope. Immunofluorescence was detected using microscopy. 
The nuclei were stained with DAPI and cells were imaged at 20× magnification.
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3.3 Obligate heterodimeric TALENs mediate efficient inhibition of HBsAg 
expression in Huh7 cells 
 
After confirming heterodimeric TALENs are expressed efficiently, antiviral efficacy was 
assessed. This was achieved by measuring the amount of secreted HBsAg which serves as a 
replication marker of HBV. Huh7 cells were transiently transfected with left and right 
TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)], pCI-neo eGFP for 
transfection efficiency and pCH-9/3091 replication competent plasmid. pCH-9/3091 mimics 
HBV replication in vitro and in vivo. Huh7 cells transfected with pUC118, pCI-neo eGFP and 
pCH-9/3091 served as a negative control. Transfections were performed in triplicate and 48 
hours after transfection the secreted HBsAg levels from the cell culture medium was 
measured. 
Equivalent GFP expression was detected in transiently transfected cells (Appendix 5.2.4). 
Huh7 cells that were transfected with CWT TALENs did not demonstrate significant HBsAg 
knockdown compared to mock treated cells with as little as 4% knockdown observed (Figure 
3.3). However cells transfected with C Variant TALENs demonstrated a significant decrease 
in HBsAg levels with 52% knockdown observed. Huh7 cells that were transfected with SWT 
and S Variant TALENs also demonstrated a significant decrease in HBsAg levels compared 
to mock treated cells with as much 84% knockdown in SWT and 80% knockdown in S 
Variant TALEN-treated cells (Figure 3.3). 
These results demonstrate that the S TALENs (both WT and Variant) which target the S ORF 
are more efficient than the C TALENs at knocking down HBsAg. Although TALEN-
mediated HBsAg knockdown is only expected to occur through direct targeted disruption of 
the S ORF by its recognition of S TALENs, it was observed that C Variant TALENs 
significantly reduced HBsAg knockdown. This suggests that C Variant TALENs could be 
inhibiting viral protein expression through transcriptional interference.  
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Figure 3.3: TALEN-mediated HBsAg knockdown in Huh7 cells. 
To determine anti-HBV activity of the TALENs, secreted HBsAg levels from culture media 
was measured. Huh7 cells were transiently transfected with left and right TALEN plasmids 
[either pCMV TALEN (WT) or pCMV TALEN (Var)] and pCH-9/3091. Cells were also 
transfected with pUC118 and pCH-9/3091 as the mock treated cells. HBsAg was assessed 48 
hours after transfection. Data obtained were averaged and the means were normalised to the 
mock. Error bars are indicative of the normalised SEM where n=3, (*: p<0.05; **: p<0.01; 
***: p<0.001). 
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3.4 In vitro TALEN-mediated targeted disruption 
 
To confirm that TALENs caused site-directed targeted disruption, a CelI assay was performed 
on HBV DNA extracted from HepG2.2.15 cells. HepG2.2.15 cells contain an integrated HBV 
sequence and as a consequence transfection with the HBV replication-competent pCH-9/3091 
plasmid was not necessary. HepG2.2.15 cells were triple-transfected with left and right 
TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)], pCI-neo eGFP was 
co-transfected to determine transfection efficiencies. HepG2.2.15 cells transfected with 
pUC118 and pCI-neo eGFP served as a negative control. 
GFP expression was readily detected in transiently transfected cells over the three weeks of 
the assay (Appendix 5.2.5). This suggests successful transfection of TALEN plasmids in the 
HepG2.2.15 cells. Total DNA was extracted from cells and the TALEN target sequences were 
amplified by PCR to produce ~520 bp amplicons (Appendix 5.2.6). These amplicons were 
then subjected to CelI treatment. CelI is a mismatch-sensitive enzyme that will detect and 
cleave heteroduplexes (Figure 3.4.1). As an internal negative control for the CelI assay 
amplicons were subjected to the same treatment but without the CelI enzyme (Appendix 
5.2.7). Wildtype and mutant HBx PCR amplicons mixed in a 1:1 ratio served as the positive 
control. 
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Figure 3.4.1: Gel electrophoresis after CelI treatment. 
The sequences spanning the predicted target sites for the C and S TALENs were amplified by 
PCR. Heteroduplexes were formed during denaturation and subsequent annealing of DNA. 
The CelI enzyme, which recognises mismatched DNA was then used to cleave the 
heteroduplexes. The cleaved products were subsequently subjected to agarose gel 
electrophoresis. DNA sequences that were unaffected by TALEN cleavage should run as one 
band. 
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Targeted disruption was not observed in the mock but was observed in the positive control 
(Figure 3.4.2). The positive control was generated by annealing a wildtype HBx amplicon 
with a mutant HBx amplicon (4 bp mismatch). This will always yield heteroduplexes that will 
be cleaved after CelI treatment. The CWT and C Variant TALENs generated 6.3% and 5.6% 
targeted disruption respectively whereas the SWT and S Variant TALENs generated 10% and 
8% targeted disruption respectively (Figure 3.4.2) 
 
Figure 3.4.2: TALEN-mediated site-directed targeted mutagenesis in HepG2.2.15 cells. 
To determine the degree of targeted disruption mediated by the TALENs in vitro, viral DNA 
was interrogated for indels. HepG2.2.15 cells were transiently transfected thrice with left and 
right TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or pUC118 
(mock). Site-directed targeted cleavage was assessed 12 days after the first transfection by the 
CelI assay. The sequences incorporating the TALE binding site for both WT and Variant 
TALENs were amplified to allow for heteroduplex formation. The resulting amplicons were 
subjected to CelI cleavage. (a) Arrow depicts CWT and C Variant mediated targeted 
disruption, (b) Arrow depicts SWT and S Variant mediated targeted disruption. (MWM: 
molecular weight marker, O’GeneRuler 1 kb DNA Ladder (Thermo Scientific, CA, USA), 
Positive (+) Control: HBx heteroduplex, negative (-) Control; pUC118). 
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3.5 Assessing potential TALEN-mediated cellular toxicity 
 
To ascertain if nuclease expression caused any toxic effects, an MTT assay was carried out on 
cells transiently transfected with TALEN vectors. MTT is a tetrazolium dye that is reduced to 
formazan which is an insoluble purple product. Mitochondrial NAD(P)H-dependent cellular 
oxidoreductase enzymes are responsible for this reduction which only occurs in viable cells. 
The amount of formazan produced is therefore an indication of cell viability. HEK293 cells 
are loosely adherent and sensitive therefore serving as a widely used model in determining 
cellular toxicity. HEK293 cells were transiently transfected with left and right TALEN 
plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)], pCH-9/3091 and pCI-neo 
eGFP. Cells were also transfected with pUC118, pCH-9/3091 and pCI-neo eGFP as a 
negative control. Additionally cells were treated with DMSO (50%) as a positive control for 
cell death. Finally, to rule out possible transfection reagent toxicity, untransfected cells were 
used. These cells were not transfected with plasmid DNA, however they received treatment 
with the same amount of transfection reagents normally used to deliver the TALENs. 
Transfections were performed in triplicate and the MTT assay was carried out 48 hours after 
transfection. 
Equivalent GFP expression was detected in transiently transfected cells (Appendix 5.2.9). 
There was no significant difference observed between TALEN-treated cells compared to the 
mock and untreated controls (Figure 3.5). This demonstrates that cellular activity of the 
TALEN-transfected cells was comparable with that of the negative controls. These results 
suggest that expression of TALENs do not cause toxicity and more importantly the anti-HBV 
effects mediated by TALENs are not caused by cellular toxicity but rather by TALEN-
mediated cleavage.  
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Figure 3.5: Absence of TALEN-associated cellular toxicity. 
To determine TALEN-associated toxicity an MTT assay was performed. HEK293 cells were 
transiently transfected with pCH-9/3091 as well as left and right TALEN plasmids [either 
pCMV TALEN (WT) or pCMV TALEN (Var)]. Mock treated cells were transfected with 
pUC118 and pCH-9/3091 only whereas cells treated with DMSO (50%) served as the positive 
control. Untransfected cells did not contain any plasmid DNA, however these cells were 
treated with transfection reagents normally used to deliver the TALENs. MTT reduction was 
assessed 48 hours after transfection. Data obtained from this assay were averaged and 
normalised to untransfected controls. Error bars are indicative of the normalised SEM where 
n=3. 
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3.6 TALEN-mediated silencing of viral gene expression in vivo 
 
3.6.1 Hydrodynamic injections of TALEN-expressing plasmids in NMRI mice 
 
Following the knockdown of HBsAg expression and targeted disruption of cccDNA observed 
in vitro, the silencing effects of TALENs against viral replication was assessed in vivo. To test 
this effect, HDI was performed in 3-5 week old NMRI mice. The injection solution contained 
left and right TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)], pCH-
9/3091 and pCI-neo FLuc (which is a luciferase gene reporter plasmid, to determine hepatic 
delivery efficiency). The mock treated mice were injected with a solution containing pUC118, 
pCH-9/3091 and pCI-neo FLuc. The experiment was carried out over a 5 day period (Figure 
3.6.1). Briefly, mice were injected on day 0 and blood samples were collected on days 3 and 5 
to assess for anti-HBV effects. Mice were sacrificed on day 5 and their livers were harvested 
to assess TALEN-mediated cleavage and HBV gene suppression as well as to assess potential 
liver induced toxicity. 
 
Figure 3.6.1: Timeline representing the experimental procedure of TALEN-treated 
mice. 
The experiment took place over 5 days. Mice were injected into their tail veins with left and 
right TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)], pCH-9/3091 
and pCI-neo FLuc. Mock treated mice were injected with pUC118, pCH-9/3091 and pCI-neo 
FLuc. Bioluminescence imagining was performed on day 3, in addition blood samples were 
collected by retro-orbital bleeding, for assessing surface protein and circulating viral particle 
equivalents as well as assessing liver toxicity by measuring ALT. Blood samples were also 
collected on day 5 by retro-orbital bleeding. The mice were then euthanised by CO2 
asphyxiation. Livers were harvested to test for targeted cleavage and HBV gene expression.  
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3.6.2 Bioluminescence imaging 
 
To confirm efficient hepatic delivery in mice, bioluminescence imaging was performed 3 days 
after injection. Bioluminescence detected Firefly luciferase expression and images infer that 
TALEN plasmids were efficiently delivered to mice livers (Figure 3.6.2). 
 
Figure 3.6.2: Bioluminescence imaging of NMRI mice. 
Mice were injected with left and right TALEN plasmids [either pCMV TALEN (WT) or 
pCMV TALEN (Var)] and pCH-9/3091, or pUC118 and pCH-9/3091 as mock treated mice. 
Additionally mice were injected with pCI-neo FLuc. Live imaging of Firefly luciferase 
expression was performed on mice on day 3 post injection. 
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3.6.3 Obligate heterodimeric TALENs mediate efficient inhibition of HBsAg 
expression in vivo 
 
After efficient hepatic delivery was observed, TALEN-mediated inhibition of HBsAg 
secretion was assessed. Compared to mock treated mice, the CWT and C Variant TALENs 
significantly reduced HBsAg by 46% and 56% on day 3, as well as 67% and 65% on day 5 
respectively (Figure 3.6.3). The SWT and S Variant TALENs significantly reduced HBsAg 
by 98% and 96% on day 3 and by 97% and 93% on day 5 respectively (Figure 3.6.3).  
These results suggest that the S TALENs were more efficient at inhibiting surface protein 
expression than the C TALENs. However the C TALEN effects seem to have improved over 
time with greater knockdown efficiencies on day 5. Collectively, both S and C TALENs 
demonstrate considerable inhibitory effects on protein expression. 
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Figure 3.6.3: TALEN-mediated HBsAg knockdown in NMRI mice. 
The HDI method was used to deliver left and right TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] and pCH-9/3091 or 
pUC118 and pCH-9/3091 as mock treated mice. To determine the anti-HBV effects of TALEN-treated mice, blood samples were collected on 
days 3 (a) and 5 (b) post-injection. HBsAg levels in mouse serum were measured by ELISA. Data obtained from this assay were averaged and 
normalised to pUC118. Error bars are indicative of the normalised SEM where n=7 (Mock and SWT treated mice), n=6 (S Variant treated mice) 
and n=5 (CWT and C Variant treated mice), (**: p<0.01; ***: p<0.001).
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3.6.4 TALEN-mediated inhibition of HBV replication in vivo 
 
To determine whether TALENs had a direct effect on HBV virion secretion, circulating VPEs 
were measured from serum samples of mice. Serum was separated from whole blood samples 
and collected on days 3 and 5. DNA was extracted and the rcDNA was quantified by real-time 
qPCR to determine the amount of circulating VPEs present in blood serum samples. 
Compared to the mock treated mice, the number of circulating VPEs in the CWT and C 
Variant TALEN-treated mice demonstrated a significant decrease (p<0.05) on day 3 (Figure 
3.6.4). By day 5 however, CWT-mediated silencing was not significantly different whereas C 
Variant treated mice demonstrated an even further decrease of circulating VPEs. Compared to 
the mock treated mice, the number of circulating VPEs in the SWT and S Variant TALEN-
treated mice also demonstrated a significant decrease (p<0.05) on day 3 (Figure 3.6.4). By 
day 5 the SWT treated mice demonstrated an even further decrease in circulating VPEs 
whereas S Variant mediated silencing was no longer significantly different. These results 
suggest that the C TALENs, particularly the C Variant TALENs, are efficient at reducing 
HBV replication. Taken together, the Variant TALENs demonstrate comparable anti-HBV 
effects as the WT TALENs. 
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Figure 3.6.4: TALEN-mediated viral replication inhibition. 
DNA was extracted from serum samples on day 3 (a) and 5 (b) post-injection. rcDNA was quantified using real-time qPCR to measure 
circulating VPEs in serum samples. Data obtained from this assay were averaged and normalised to pUC118. Error bars are indicative of the 
normalised SEM where n=7 (Mock and SWT treated mice), n=6 (S Variant treated mice) and n=5 (CWT and C Variant treated mice), (*: 
p<0.05).
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3.6.5 In vivo TALEN-mediated repression of HBV core and surface transcripts 
 
Following anti-HBV effects on surface protein production and viral replication inhibition, the 
anti-HBV effects of TALENs on transcription were assessed. pgRNA plays an important role 
in HBV gene expression. It serves as a template for reverse transcription leading to the 
formation of partially double-stranded rcDNA [reviewed in (Seeger and Mason, 2000)]. The 
rcDNA is also the precursor for cccDNA. Furthermore the presence of hepatic pgRNA is 
indicative of viral persistence and active gene expression (Bai et al., 2013). To measure HBV 
gene expression in TALEN-treated mice, RNA was extracted from the murine liver samples 
and converted to cDNA. The pgRNA and HBV surface mRNA levels were measured by 
qPCR and relativised to mGAPDH.  
Compared to mock treated mice, all TALENs demonstrated a significant reduction in pgRNA 
levels where CWT- and C Variant-treated mice demonstrated an 89% and 79% decrease 
respectively (Figure 3.6.5). SWT- and S Variant-treated mice demonstrated an 89% and 88% 
decrease respectively (Figure 3.6.5). Only the S TALEN-treated mice demonstrated a 
significant reduction in surface mRNA levels (Figure 3.6.5). The BCP drives expression of 
pgRNA whereas pre-S1 and pre-S2 promoters drive expression of the two surface mRNAs. 
Taken together these results demonstrate that the Variant TALENs are as effective as the WT 
TALENs in suppressing transcription from the BCP however the S TALENs are only 
effective in suppressing transcription from the pre-S1 and pre-S2 promoters, particularly the S 
Variant TALEN.  
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Figure 3.6.5: In vivo TALEN-mediated knockdown of HBV mRNA. 
To measure HBV gene expression in TALEN-treated mice, HBV mRNA levels were measured from murine liver samples on day 5 post HDI. (a) 
pgRNA and (b) surface mRNA levels were measured by qPCR and relativised to murine GAPDH mRNA levels. Means were calculated and 
normalised to pUC118. Error bars are indicative of the normalised SEM where n=7 (Mock and SWT treated mice), n=6 (S Variant treated mice) 
and n=5 (CWT and C Variant treated mice), (*: p<0.05).
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3.6.6 In vivo TALEN-mediated targeted disruption 
 
To confirm that TALENs caused targeted disruption, a CelI assay was performed on HBV 
DNA extracted from liver samples of mice (as described in section 3.1.2). In addition to the 
mock control, an HBx heteroduplex sequence was used as a positive control. PCR products 
are illustrated in the Appendix (5.3.3 and 5.3.4).  
Targeted disruption was not observed in the mock controls but was observed in the HBx 
heteroduplex sequence (Figure 3.6.6). The CWT and C Variant amplicons generated 11.6% 
and 13% targeted disruption respectively whereas the SWT and S Variant amplicons 
generated 14.6% and 15.2% targeted disruption respectively (Figure 3.6.6). These results 
suggest that the TALENs are capable of causing targeted disruption within HBV-encoded 
DNA, resulting in the inhibition of surface proteins observed in prior experiments. 
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Figure 3.6.6: TALEN-mediated targeted disruption of HBV-encoding DNA in murine liver samples. 
To determine the levels of targeted disruption mediated by the TALENs in vivo, total DNA was extracted from murine liver and target sites 
amplified by PCR to allow for heteroduplex formation. The resulting amplicons were subjected to CelI cleavage assays. Arrows depict (a) CWT 
targeted disruption, (b) C Variant targeted disruption, (c) SWT targeted disruption and (d) S Variant targeted disruption.(MWM: molecular 
weight marker, O’GeneRuler 1 kb DNA Ladder (Thermo Scientific, CA, USA), Positive (+) Control: HBx heteroduplex, negative(-) Control; 
pUC118). 
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3.6.7 In vivo liver toxicity analysis 
 
The administration of TALENs in vivo could potentially be cytotoxic as a result of DSBs at 
unintended sites (Bloom et al., 2013). To ensure that TALEN-mediated effects in all in vivo 
experiments were non-toxic, ALT levels, which are indicative of liver damage, were 
measured (Figure 3.6.7). ALT levels were comparable between mock and TALEN-treated 
mice. Importantly ALT levels did not exceed the threshold of 100 IU/L demonstrating that 
there was no significant TALEN-associated toxicity. 
 
Figure 3.6.7: Absence of hepatic toxicity in TALEN-treated NMRI mice. 
To determine in vivo TALEN-associated toxicity, ALT levels were measured in serum of 
mock and TALEN-treated mice at day 5 after injection. No significant hepatotoxicity was 
observed. Data obtained from individual samples are represented where n=7 (Mock and SWT 
treated mice), n=6 (S Variant treated mice) and n=5 (CWT and C Variant treated mice). 
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Overall the results obtained from this study indicate that obligate heterodimeric TALENs 
exhibit anti-HBV effects on replication, surface protein production and gene expression of 
HBV. The CelI assay correlates with the TALEN-mediated effects as these TALENs are 
capable of inducing targeted disruption with no significant cellular toxicity observed in either 
in vitro or in vivo settings. Taken together these results demonstrate the first successful use of 
obligate heterodimeric TALENs against HBV. 
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Chapter 4 
4. Discussion 
HBV infection rates remain high, particularly in hyperendemic regions such as sub-Saharan 
Africa and Asia (Luo et al., 2012). Chronic HBV infection occurs as a result of the persistence 
of cccDNA (Werle–Lapostolle et al., 2004). In South Africa alone, 2.5 million people are 
chronically infected (Spearman and Sonderup, 2014). cccDNA serves as a template for viral 
RNA transcription which is subsequently translated to viral protein. While current treatment 
effectively inhibits the reverse transcription of pregenomic RNA, it is largely ineffective in 
eradicating cccDNA (Werle–Lapostolle et al., 2004). In addition, cccDNA remains episomal 
and can reside in the nucleus to continuously produce viral RNA. (Rehermann et al., 1996). A 
therapeutic approach targeting cccDNA directly is therefore greatly needed to combat chronic 
infection.  
4.1 Wildtype TALENs are prone to off-target effects 
 
TALENs have emerged as an effective tool in targeting cccDNA. The development of several 
cloning strategies allowed for efficient assembly of custom TALE arrays (Cermak et al., 
2011), giving rise to a widely used gene editing tool. In comparison to ZFNs, which function 
in a similar fashion, TALENs exhibit improved specificity and adaptability towards targeted 
cleavage. Previous studies have demonstrated significant viral replication inhibition and 
successful disabling of cccDNA with the use of TALENs (Bloom et al., 2013). However the 
wildtype FokI nuclease domain used in the design of these TALENs may be prone to off-
target effects (Mussolino et al., 2014, Pattanayak et al., 2014). Off-target effects are highly 
undesirable in a therapeutic context hence this study highlights the importance of the use of 
obligate heterodimeric TALENs. 
4.2 Successful generation of obligate heterodimeric TALENs 
 
This study is the first to demonstrate the use of obligate heterodimeric TALENs targeted 
against HBV cccDNA. These TALENs have been modified to comprise obligate 
heterodimeric FokI nuclease domain variants. The variant nuclease domains were designed to 
be more specific to site-directed cleavage thus preventing off-target effects. Obligate 
heterodimeric TALENs serve as a novel candidate therapeutic approach against the virus, 
targeting cccDNA and subsequently inhibiting HBV replication. 
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4.2.1 Obligate heterodimeric TALENs inhibit HBV replication 
 
The obligate heterodimeric TALENs were designed to target the C and S ORFs. As a result of 
the remarkably compact viral genome, S and C TALENs also target the overlapping P ORF 
(Bloom et al., 2013). This study demonstrated that the S Variant TALEN reduced secreted 
HBsAg levels by 80% which was comparable to the SWT TALEN which knocked down 
HBsAg by 84% in vitro. Interestingly the C Variant TALEN also reduced HBsAg by 52%. 
Furthermore both C and S TALENs from WT and Variants were shown to significantly 
reduce secreted HBsAg levels on days 3 and 5 in vivo. The effects on HBsAg knockdown 
from the C TALENs were more apparent in the in vivo samples.  
The circulating VPEs were significantly reduced by all TALENs on day 3 and only 
significantly reduced by the C Variant and SWT TALENs on day 5; however CWT and S 
Variant TALEN treated mice still demonstrated reductions of greater than 50% by day 5 in 
vivo. The core protein plays an important role in assembling into its capsid-like structure, 
surrounding the genome. The effect of the C TALENs leads to mutations in the C ORF. This 
results in mutated RNA which subsequently leads to mutations in the core protein. The core 
protein is still produced but it is mutated so extensively that it is non-functional. Consequently 
it cannot encapsidate pgRNA which in turn prevents assembly thus inhibiting new virion 
formation. This coincides with the decrease observed in surface protein knockdown. The S 
TALENs demonstrated considerable knockdown of surface proteins as well as circulating 
VPEs. This suggests that the S TALENs are cleaving at their binding sites and causing 
mutations in the DNA which in turn causes in mutations in the protein, resulting in non-
functional protein. This means that virion assembly does not proceed correctly therefore 
inactivating viral replication. 
In a study by Bloom et al HBV gene expression was not affected by the WT TALENs as these 
TALENs were shown to induce mutations at targeting sites resulting in truncated protein 
production (Bloom et al., 2013). Unexpectedly the data from this study contradicts the 
findings of Bloom et al as both WT and Variant TALENs displayed considerable knockdown 
of intrahepatic viral RNA levels demonstrating that these TALENs exhibit transcriptional 
interference. As previously mentioned, the C ORF encompasses the BCP promoter and the S 
ORF encompasses the pre-S1 and pre-S2 promoters. It is possible that the TALENs 
transcriptionally interfere with these promoters therefore exhibiting indirect transcriptional 
inhibition of HBV gene expression. Indeed a similar occurrence was observed by Bloom and 
colleagues whereby TALENs targeted against the P ORF significantly reduced HBsAg and 
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this was likely caused by transcriptional interference rather than direct cleavage (Bloom et al., 
2013). 
4.2.2 Obligate heterodimeric TALENs mediate targeted cleavage of HBV DNA 
 
To determine whether the anti-HBV effects that were observed in treated samples were as a 
result of TALEN binding and cleavage of cognate target sites, targeted cleavage efficiency 
was assessed using the CelI mismatch sensitive enzyme. In this study HepG2.2.15 cells were 
used for in vitro targeted cleavage testing and NMRI mice were used for in vivo targeted 
cleavage testing. In the HepG2.2.15 cells the CWT and C Variant TALENs demonstrated 
6.3% and 5.7% targeted disruption respectively whereas the SWT and S Variant TALENs 
demonstrated 10% and 8% targeted disruption respectively. In murine hepatocytes, all 
TALENs demonstrated higher cleavage efficiencies compared to the in vitro results. The 
obligate heterodimeric TALENs demonstrated higher targeted cleavage compared to the WT 
TALENs in vivo.  
The inconsistent targeted cleavage data observed between in vitro and in vivo samples from 
the same TALEN can be explained by a number of factors. In HepG2.2.15 cells, transfection 
efficiencies could affect TALEN efficacy, because these cells are difficult to transfect and 
even after three transfections only 65-70% of the cells expressed TALENs. pCH-9/3091 HBV 
replication competent plasmids are introduced into murine hepatocytes by the HDI method. 
However NMRI mice are not predisposed to HBV infection therefore cccDNA pools are not 
established. Despite the absence of active infection, viral replication still takes place and 
results in the secretion of new virions as well as circulating VPEs (Yang et al., 2002). 
HepG2.2.15 cells unlike murine hepatocytes are capable of establishing cccDNA and produce 
up to 10 more cccDNA copies per cell compared to normal chronically infected hepatocytes 
(Rabe et al., 2006). HepG2.2.15 cells retain substantial cccDNA pools, therefore TALEN 
efficacy will be underestimated in these cells.  
Compared to the investigation by Bloom et al, this study demonstrated far less targeted 
cleavage efficiencies (Bloom et al., 2013). This could be explained by use of CelI as opposed 
to T7 endonuclease 1 (T7E1) to measure targeted mutation. CelI may not be as sensitive in 
detecting targeted cleavage (Vouillot et al., 2015).Furthermore, in this study total DNA was 
extracted from HepG2.2.15 cells. To improve estimation of targeted cleavage efficiency, the 
CelI assay should be conducted on cccDNA-enriched DNA extractions. In order to enrich for 
cccDNA, a Hirt extraction of treated cells followed by plasmid safe ATP-dependent DNase 
treatment (PSADT) needs to be performed. The Hirt extraction procedure extracts low 
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molecular weight DNA such as plasmids and will therefore include both cccDNA and rcDNA 
(Bloom et al., 2013).  
Genomic DNA contamination is typically negligible in Hirt extractions as demonstrated by 
amplification of genomic sequences (e.g. alpha-1 antitrypsin) (Bloom et al., 2013). PSADT 
degrades linear and circular single-stranded DNA such as rcDNA while leaving cccDNA 
intact. Hirt extraction followed by PSADT therefore enriches for cccDNA and analysis of this 
preparation indicates an effect on cccDNA. However a major disadvantage of PSADT is that 
it also degrades nicked cccDNA and so the TALEN-mediated effects on cccDNA could be 
underestimated. 
4.2.3 Obligate heterodimeric TALENs do not illicit cytotoxic effects 
 
One of the biggest challenges facing gene therapy is unwanted cytotoxic effects upon the 
introduction of exogenous DNA. Unlike the most widely used ZFNs, TALEN design is more 
specific due to single nucleotide recognition as opposed to triple nucleotide recognition 
(Elrod-Erickson et al., 1996, Yan et al., 2013). Granted that TALENs were designed for 
improved target site recognition they have also shown diminished cytotoxicity in previous 
studies (Bloom et al., 2013, Chen et al., 2014). In this study the MTT assay demonstrated that 
HEK293 cells were not negatively affected after TALEN treatment, moreover, cells remained 
viable and TALENs were not associated with cytotoxicity. The MTT assay does however 
have a major limitation in that tetrazolium reduction represents cellular metabolism and not 
viable cell numbers [reviewed in (Berridge et al., 2005)]. Cellular metabolism rates can differ 
between viable cells. However to further test for potential liver cytotoxicity, ALT activity 
which is a biomarker for liver health was measured. ALT levels remain one of the most 
widely used indicators of liver damage and are often used by several investigators when 
assessing liver health (Anderson et al., 2000, Chiu et al., 2017, Mahady et al., 2017). TALEN 
treated samples did not present significantly raised ALT levels. Taken together these data 
confirms that the obligate heterodimeric TALENs are not cytotoxic, suggesting that off-target 
effects are minimal. 
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4.3 Obligate heterodimeric TALENs represents a safe and efficient tool 
for disabling HBV replication 
 
Obligate heterodimeric TALENs have shown comparable effects against HBV replication to 
that of the WT TALENs. This is promising as one of the potential drawbacks associated with 
heterodimeric FokI nuclease domains is that in the process of preventing off-targeted cleavage 
they reduce hybridisation energy between L and R monomers (Szczepek et al., 2007). The 
reduction in hybridisation energy essentially means that cleavage efficiencies will also be 
reduced to ensure safer toxicity profiles. Interestingly, it has been observed that obligate 
heterodimeric TALENs display comparable or higher cleavage efficiencies against HBV 
replication with no evidence of cellular toxicity.  
4.4 Current challenges hindering successful HBV therapy 
 
An important aspect to consider for gene therapy is tissue specificity. Because HBV affects 
hepatocytes it is important for the TALENs to target the liver only. Replacement of the 
ubiquitous CMV promoter with a liver-specific promoter would thus be preferable. Two such 
promoters include the modified murine transthyretin (mTTR) and phosphoenolpyruvate 
carboxykinase (PEPCK) transcriptional regulatory elements. mTTR promoters have been 
used to reduce HBV replication through expression of artificial primary microRNAs in 
cassettes delivered with helper-dependent adenoviruses (Mowa et al., 2014). The PEPCK 
promoter has demonstrated long-term liver-specific transgene activity (Mian et al., 2004, 
Brunetti-Pierri et al., 2007). 
One of the challenges of gene therapy is identifying good animal models. The HBV 
transgenic mice, initially developed by Chisari et al comprised the HBV envelope, core, 
precore or X sequences (Chisari et al., 1985, Milich et al., 1990, Kim et al., 1991). This 
mouse model was further developed by Guidotti et al to comprise 1.3×greaterthan-genome 
length HBV DNA integrated into the host genome (Guidotti et al., 1994). This model allows 
for constant HBV replication which leads to a continuous secretion of new virions. However 
these mice do not naturally recapitulate HBV infection and cccDNA pools are still not 
established, nevertheless this model will still be useful for determining TALEN-mediated 
targeted disruption of integrated HBV sequences. To circumvent the lack of naturally 
occurring HBV infection in mice, researchers ablated the entire mouse liver and transplanted 
human hepatocytes into mice. This resulted in chimaeric mice which are susceptible to HBV 
infection and more importantly a cccDNA pool is established (Meuleman et al., 2005, 
Meuleman and Leroux-Roels, 2008). 
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The need for a safe yet effective delivery vehicle is crucial to ensure long-lasting TALEN-
mediated therapeutic effects. The delivery of naked DNA into animal models are associated 
with several undesirable drawbacks such as degradation by intra- and extracellular enzymes 
as well as difficulties in passing through the plasma membrane by large, negatively charged 
therapeutic nucleic acid sequences (Schreier, 1994). Both viral and non-viral vectors have 
been developed for the delivery of therapeutic genes (Nayerossadat et al., 2012). Viral vectors 
have been exploited for their natural replication and tropism characteristics. In recent years a 
number of viral vectors have been developed for use of gene therapy.  
These include lentiviruses (Connolly, 2002), adenoviruses (SM Wold and Toth, 2013) and 
AAVs (Daya and Berns, 2008, Maepa et al., 2017). Several non-viral delivery mechanisms 
have also been established. These include particle bombardment, electroporation and 
chemical carriers which are lipid- and polymer-based (Lee and Lee, 2012, Ramamoorth and 
Narvekar, 2015). Each delivery vector exhibits both advantages and disadvantages so there is 
no “one-measure-fits-all” resolution to gene therapy delivery.  
To date there has not been any data published on the use of mTTR or PEPCK promoters for 
TALEN-mediated targeting of HBV. It would therefore be beneficial to explore use of liver-
specific promoters coupled with a delivery system to ensure long-term obligate heterodimeric 
TALEN-mediated expression. Another consideration would be to convert TALEN-encoding 
sequences to mRNA. There are several advantages associated with the use of TALEN mRNA 
as a therapy. Some of which are i) there is no risk of genome integration upon entering the 
cell, ii) mRNA is easily scalable as transcription can take place in vitro and iii) since mRNA 
functions in the cytoplasm, it will have immediate effect in the cell upon endocytosis whereas 
DNA needs to access the nucleus (Youn and Chung, 2015).  
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4.5 Conclusion 
 
Taken together this study demonstrates that obligate heterodimeric TALENs are capable of 
mediating anti-HBV effects by targeting cccDNA and silencing HBV replication. Both C and 
S Variant TALENs were capable of significantly reducing HBsAg expression in vitro and in 
vivo. Furthermore these TALENs were shown to reduce circulating VPEs by more than 64% 
and pgRNA as well as surface mRNA levels by more than 78%. The effects of C TALENs 
against HBsAg, VPEs and HBV surface mRNA reductions demonstrate that these TALENs 
have an indirect, yet effective response against HBV surface protein production. Finally 
targeted cleavage was observed both in vitro and in vivo without any cytotoxic effects. The 
obligate heterodimeric TALENs have been proven to significantly reduce HBV replication 
showing promise as a curative approach against the virus. 
4.6 Future studies 
 
The obligate heterodimeric TALENs demonstrated comparable results with the WT TALENs 
throughout all experiments. Assessing off-target effects by bioinformatic analysis using 
Predicted Report of Genome-wide Nuclease Off-target Sites (PROGNOS) software and 
selective Next-generation sequencing (NGS) should therefore be considered to ultimately 
determine the cleavage specificity of obligate heterodimeric TALENs. Long-term objectives 
include converting TALEN-encoding sequences to mRNA. mRNA is safer for incorporation 
into non-viral vectors, therefore the obligate heterodimeric TALEN DNA will serve as a 
template for in vitro transcription to mRNA and will be encapsulated by modified liposomes. 
The obligate heterodimeric TALEN mRNA, together with the lipoplex delivery system will 
facilitate long-term therapy against HBV chronic infection. 
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Chapter 5 
5. Appendix 
5.1 Generation of anti-HBV obligate heterodimeric TALENs 
5.1.1 Agarose gel electrophoresis protocol 
 
Material required 
o 50× Tris Acetate EDTA (TAE) Buffer 
o Agarose  
o TAE (50×) was made by adding 242 g of Tris base, 57.1 mL of glacial acetic acid and 
100 mL of 500 mM EDTA to 700 mL of dH2O. pH was adjusted to 8 and the solution 
adjusted to a volume of 1 L. 
o Ethidium bromide (10 mg/mL) 
Procedure: 
A 1% agarose gel was made by weighing out 1 g of agar into 100 mL of 1× TAE buffer in a 
flask. For 1.5% and 2% agarose gels, agar was weighed out to 1.5 g and 2 g respectively. This 
mixture was heated in a microwave for 5 minutes and allowed to cool at room temperature for 
5 minutes after which 3 µL of ethidium bromide was added to the flask and slowly stirred. 
The liquid gel was then poured into a casting tray and the appropriate gel combs were inserted 
into the gel. The gel was left to solidify at room temperature for 20 minutes. After loading the 
samples the gel was set to run at 120 V for 30 minutes or until DNA was sufficiently 
resolved.  
For the CelI experiment a 2% agarose gel was run at 80 V for 8 minutes and then 120 V for 5 
minutes. Cleavage products can become faint after prolonged electrophoresis at high voltage. 
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5.1.2 pCMV TALEN (WT) and pAC AAVS1 plasmid maps 
 
 
Figure 5.1: pCMV TALEN (WT) plasmid map. 
This vector sequence encodes a CMV promoter which drives the expression of WT TALEN 
monomers (TALE plus WT FokI nuclease domain), a HA epitope serving as a protein tag to detect 
TALEN expression as well as a nuclear localisation signal (NLS), signalling transport to the nucleus 
once translated. This plasmid confers resistance to neomycin and kanamycin (NeoR/KanR). 
Restriction enzymes used in the cloning strategy are indicated on the map. The map was generated 
using SnapGene® (available at snapgene.com).          
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Figure 5.2: pAC AAVS1 left and right TALEN Variant. 
The left (top vector) and right variant (bottom vector) FokI nuclease domain-encoding sequences are 
driven by a CMV promoter. The plasmid confers resistance to ampicillin (AmpR). Restriction 
enzymes used in the cloning strategy are indicated on the map. The map was generated using 
SnapGene® (available at snapgene.com).      
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5.1.3 Gel electrophoresis images of TALE and nuclease generation 
 
 
Figure 5.3: One percent agarose gel electrophoresis of C and SWT TALENs. 
ApaI and BamHI restriction digestion generated two bands, 5 284 bp and 601 bp in size. The top bands 
(indicated in red) were excised and purified. (MWM: molecular weight marker, O’GeneRuler 1 kb 
DNA Ladder, Thermo Scientific, CA, USA). 
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Figure 5.4: One percent agarose gel electrophoresis of plasmids encoding heterodimeric 
FokI nuclease. 
ApaI and BamHI restriction digestion generated two bands, 5 679 bp and 601 bp in size. The bottom 
bands (indicated in red) were excised and purified. (MWM: molecular weight marker, O’GeneRuler 1 
kb DNA Ladder, Thermo Scientific, CA, USA). 
 
 
 
 
 
 
 
 
 
 
Chapter 5-Appendix 
85 
 
5.1.4 Left and right FokI multiple protein sequence alignment 
 
Reference sequence (FokI Left Variant domain sequence)                 
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
CL WT                
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
SL WT                
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
CL Variant       
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
SL Variant 
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
 
Reference sequence (FokI Left Variant domain sequence)                
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMERYVEENQTRNKHANP 
CL WT                
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINP 
SL WT                
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINP 
CL Variant 
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMERYVEENQTRNKHANP 
SL Variant      
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMERYVEENQTRNKHANP 
 
Reference sequence (FokI Left Variant domain sequence)                
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
CL WT                
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
SL WT                
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
CL Variant 
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
SL Variant 
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
 
Reference sequence (FokI Left Variant domain sequence) 
TLTLEEVRRKFNNGEINF*GP 
CL WT                 
TLTLEEVRRKFNNGEINF*GP 
SL WT                 
TLTLEEVRRKFNNGEINF*G 
CL Variant  
TLTLEEVRRKFNNGEINF*GP 
SL Variant  
TLTLEEVRRKFNNGEINF*GP 
 
Figure 5.5: Heterodimeric left FokI multiple sequence alignment. 
Displayed are the aligned FokI amino acid sequences from the pCMV CL/SL TALEN (WT), pCMV 
CL/SL TALEN (Var) plasmids compared with the reference sequence (FokI Left Variant domain 
sequence). The mutations Q486E and I499A are indicated in purple and the WT sequences are 
indicated in blue. 
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Reference sequence (FokI Right Variant domain sequence) 
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
CR WT                
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
SR WT                
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
CR Variant 
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
SR Variant 
GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK 
 
Reference sequence (FokI Right Variant domain sequence) 
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINP 
CR WT                
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINP 
SR WT                
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINP 
CR Variant 
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINP 
SR Variant 
HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINP 
 
Reference sequence (FokI Right Variant domain sequence) 
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHVTNCNGAVLSVEELLIGGEMIKAG 
CR WT                
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
SR WT                
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG 
CR Variant 
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHVTNCNGAVLSVEELLIGGEMIKAG 
SR Variant 
NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHVTNCNGAVLSVEELLIGGEMIKAG 
 
Reference sequence (FokI Right Variant domain sequence 
TLTLEEVRRKFNNGEINF*GP 
CR WT                 
TLTLEEVRRKFNNGEINF*GP 
SR WT                 
TLTLEEVRRKFNNGEINF*GP 
CR Variant  
TLTLEEVRRKFNNGEINF*GP 
SR Variant  
TLTLEEVRRKFNNGEINF*GP 
 
Figure 5.6: Heterodimeric right FokI multiple sequence alignment. 
Displayed are the aligned FokI amino acid sequences from the pCMV CR/SR TALEN (WT), pCMV 
CR/SR TALEN (Var) plasmids compared with the reference sequence (FokI Right Variant domain 
sequence). The mutations E490K and I538V are indicated in purple and the WT sequences are 
indicated in blue. 
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5.1.5 Gel extraction protocol 
 
Material required 
o QIAquick® Gel Extraction Kit (Qiagen, Hilden, Germany) 
o G:BOX UV transilluminator (Syngene, Cambridge, UK). 
Procedure 
All centrifugation steps were carried out at room temperature at maximum speed in a 
benchtop centrifuge. DNA bands were excised from the gel using a clean sharp blade. The 
excised gel pieces were weighed and 3 volumes of buffer QG was added to 1 volume of gel. 
This was incubated at 50 °C until the gel pieces were completely dissolved. One gel volume 
of isopropanol was added to the dissolved gel, vortexed and then transferred to QIAquick 
Spin Columns. This was centrifuged for 1 minute and the flow-through was discarded. Seven 
hundred and fifty microlitres of wash buffer PE was added to the columns and centrifuged for 
1 minute. The flow-through was discarded and the column was centrifuged for an additional 
minute to remove any excess wash buffer. The column was transferred to a clean 
microcentrifuge tube and the DNA was eluted by adding 35 µL of dH2O to the column 
(allowing it to stand at room temperature for 5 minutes to increase DNA yield) followed by 
centrifugation and stored at -2 °C 
In the case of PCR clean-ups, 300 µL of buffer QG was added to the PCR products followed 
by adding 150 µL of isopropanol. This mixture was transferred to the QIAquick Spin 
Columns. The remaining procedure was then followed as above. 
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5.1.6 Ligation molar ratios 
 
Table 5.1: Ligation of FokI insert: TALE backbone 
Insert Vector backbone Molar ratio (Insert: 
backbone) 
Left variant FokI Left Core TALE 3:1 
Right variant FokI Right Core TALE 9:1 
Left variant FokI Left Surface TALE 9:1 
Right variant FokI Right Surface TALE 3:1 
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5.1.7 Preparation and transformation of CaCl2competentbacterial cells 
 
Material required 
o Escherichia coli cells 
o  Luria Bertani medium  
Ten grams of tryptone, 5 g of yeast extract and 5 g of NaCl was added together in 1 L of 
dH2O. This solution was autoclaved at 121 °C and 1 kg/cm
2
 for 20 minutes. Luria Bertani 
medium was cooled and stored at room temperature. 
o Ampicillin (100 mg/mL) 
1000×stock (100 mg/mL) = 1 g/10 mL 
∴1 g in 5mL of dH2O and 5 mL of 100% ethanol and stored at -20 °C 
o Transformation buffer 
Transformation buffer was made by adding 1.4702 g of CaCl2.H2O (100 mM), 0.3024 g of 
PIPES (10 mM) and 15 mL of glycerol together in 80 mL of dH2O. The pH of this solution 
was adjusted to 7 and dH2O was added up to 100 mL. This solution was autoclaved at 121 °C 
and 1 kg/cm
2
 for 20 minutes. Transformation buffer was stored at -20 °C. 
Procedure: 
Twenty microlitres of E. coli were added into 10 mL of Luria Bertani medium and grown 
overnight at 37 °C in a shaking incubator. As a negative control to ensure that E. coli was not 
contaminated, 20 µL of E. coli was added into 10 mL of Luria Bertani medium containing 
ampicillin to a concentration of 100 µg/mL. Following overnight incubation, 10 mL of the 
bacterial culture was transferred to 150 mL of Luria Bertani medium and this was incubated at 
37 °C for 4 hours in a shaking incubator. The bacterial culture was divided into three 50 mL 
tubes and centrifuged for 25 minutes at 2000 ×g at 4 °C. The supernatant was discarded and 
the pellet was resuspended in 1 mL of transformation buffer. The resuspensions were pooled 
together in one tube and made up to 35 mL with transformation buffer. This was incubated on 
ice for 30 minutes and then centrifuged for 10 minutes at 1000 ×g at 4 °C. The supernatant 
was discarded and the pellet was resuspended in 2 mL of transformation buffer. Smaller 
volumes of this solution were aliquoted and stored at -80 °C. 
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Transformation 
Material required 
o Chemically competent E. cells 
o Luria Bertani medium containing agar (Oxoid Ltd, Hampshire, England) 
o 1000× Ampicillin  
o 1000× Kanamycin  
1000× stock (40 mg/mL) = 0.4 g/10 mL 
∴0.4 g in 10 mL of dH2O, filter sterilised and stored at -20 °C 
o Agar plates 
One and a half grams of agar (Oxoid Ltd, Hampshire, England) was added to 500 mL of Luria 
Bertani medium solution. This solution was autoclaved at 121 °C and 1 kg/cm
2
 for 20 
minutes. Agar solution was left to cool for 30-45 minutes and either ampicillin or kanamycin 
was added to a final concentration of 100 µg/mL or 40 µg/mL, respectively. The agar solution 
was poured into petri dishes and left to solidify at room temperature for an hour. Plates were 
stored at 4 °C. 
Procedure 
Plasmid DNA not exceeding 10 µL was added to 100 µL of competent E. coli and incubated 
on ice for 30 minutes followed by heat shock activation at 42 °C for 2 minutes. E. coli were 
then left to recover on ice for 5 minutes prior to plating on agar plates containing Luria 
Bertani medium supplemented with 100 µg/mL ampicillin or 40 µg/mL kanamycin. The 
plates were sealed and left incubating at 37 °C overnight. 
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5.1.8 Small scale plasmid preparation 
 
Material required 
o EconoSpin™ All-in-One Mini Spin Columns, (Epoch Life Sciences, TX, USA). 
o MX1 buffer (6.06 g Tris-HCl, 3.72g EDTA, RNaseA (100 µg/mL), pH 8.01 in 1 L) 
o MX2 buffer (8 g NaOH, 10 g SDS in 1 L) 
o MX3 buffer (294.5 g potassium acetate, pH 4.2 in 1 L) 
o WS buffer (1.2 g Tris-HCl, 80% ethanol, pH 7.56 in 1 L)  
o Bacterial culture 
Procedure 
Pellets were harvested from 10 mL bacterial culture by centrifuging at 10 000 ×g for 1 
minute. The supernatant was discarded and 250 µL MX1 Buffer was added to the pellet and 
mixed by pulse-vortexing. The resuspension was transferred to a microcentrifuge tube. Two 
hundred and fifty microlitres of MX2 Buffer was then added to the resuspension and gently 
mixed by inverting the tube 5 times. This was incubated at room temperature for 5 minutes 
after which 350 µL of MX3 Buffer was added and gently mixed by inversion. The solution 
was centrifuged at 14 000 ×g for 10 minutes. The supernatant was then carefully transferred 
to EconoSpin™ All-in-One Mini Spin Column and centrifuged at 2000 ×g for 1 minute. The 
flow-through was discarded and 500 µL WS Buffer was added to the columns followed by 
centrifugation at 14 000 ×g for 1 minute. This step was repeated and the flow-through was 
discarded. An additional 1 minute spin at 14 000 ×g was repeated to remove residual buffer. 
The flow-through was discarded and the column was transferred to a new microcentrifuge 
tube. The DNA was eluted by adding 100 µL of dH2O to the column and centrifuged at 
maximum speed in a benchtop centrifuge for 1 minute. DNA was stored at -20 °C. 
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5.1.9 Large scale plasmid preparation 
 
Material required 
o QIAGEN Plasmid Maxi Kit (Qiagen, Hilden, Germany) 
o Bacterial culture 
Procedure 
For bulk plasmid preparation, plasmids were transformed as described in 5.1.7. One colony 
was selected and added to 200 mL of Luria Bertani medium containing either ampicillin or 
kanamycin and grown overnight at 37 °C in a shaking incubator. Pellets were harvested from 
200 mL bacterial culture by centrifuging at 6000 ×g for 15 minutes at 4 °C. The supernatant 
was discarded and the pellet was resuspended in 10 mL of buffer P1. Ten millilitres of buffer 
P2 was then added to the resuspensions mixed by inversion and incubation at room 
temperature for 5 minutes. Ten millilitres of buffer P3 was added and mixed by inversion and 
centrifuged at 20 000 ×g for 30 minutes at 4 °C. During centrifugation, 10 mL of buffer QBT 
was added to a QIAGEN-tip 500 to equilibrate it. After centrifugation the supernatant was 
filtered through a cloth sieve and carefully applied to the QIAGEN-tip. The supernatant was 
allowed to enter the resin of the QIAGEN-tip by gravity flow. Once the supernatant 
completely passed through the QIAGEN-tip it was washed twice with 30 mL of buffer QC. 
The QIAGEN-tip was transferred to a 50 mL tube and the DNA eluted with 15 mL of QN 
buffer. DNA was precipitated by adding 10.5 mL of isopropanol and centrifuging at 15 000 
×g for 40 minutes at 4 °C. The supernatant was discarded and the pellet was washed in 5 mL 
of 70% ethanol and centrifuged at 15 000 ×g for 20 minutes at 4 °C. The supernatant was 
carefully discarded and the pellet air dried for 10 minutes. The pellet was then dissolved in 
100 µL of dH2O. The purity and concentration of DNA was determined by 
spectrophotometry. 
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5.2 In vitro experiments 
5.2.1 Mycoplasma detection 
 
Material required 
o MycoAlert™ Mycoplasma Detection kit (Lonza, Basel, Switzerland) 
o Cell culture 
Procedure 
Two millilitres of cell culture supernatant was added to a microcentrifuge tube and 
centrifuged at 200 ×g for 3 minutes. One hundred microlitres of the supernatant was 
transferred to a clean tube. One hundred microlitres of MycoAlert™ reagent was added to the 
supernatant and incubated at room temperature for 5 minutes. The luminescence was then 
measured with the Veritas™ Microplate Luminometer (Promega, WI, USA) (reading A). One 
hundred microlitres of MycoAlert™ substrate was added to the supernatant and this was 
incubated at room temperature for 10 minutes. The luminescence was again measured 
(reading B). The ratio of reading B/reading A was calculated with a value < 0.9 indicating no 
mycoplasma contamination, 0.9-1.2 being borderline and a value >1.2 being positive for 
mycoplasma contamination. 
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5.2.2 Transfection mixes 
 
Lipofectamine® 3000  
Cells were transfected 24 hours after seeding. A maximum of 2500 ng of DNA was required 
for the DNA-Lipid complex of a 6-well plate. Lipofectamine® 3000 and Opti-MEM 
(Gibco®, BRL, UK) were required to make the DNA-Lipid complex according to the volumes 
indicated in Table 5.2. This was incubated at room temperature for 15 minutes. Following the 
incubation, 250 µL of the transfection mix was added to each well. A maximum of 100 ng of 
DNA was required for the DNA-Lipid complex of a 96-well plate. This was incubated at 
room temperature for 15 minutes. Following the incubation, 10 µL of the transfection mix 
was added to each well. 
Polyethylenimine 
Cells were transfected 6 hours after seeding. For the DNA-PEI complex of a 96-well plate, 
3.125 µL of NaCl and dH2O up to 6.25 µL was added to 250 ng of DNA. For the PEI dilution 
in a 96-well plate, 3.125 µL of PEI (10×), 5 µL of NaCl and 2.5 µL of dH2O was mixed and 
added to the DNA-PEI complex. This was incubated at room temperature for 20 minutes. 
Following the incubation, 12.75 µL of the transfection mix was added to each well. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5-Appendix 
95 
 
Table 5.2: Lipofectamine® 3000 Transfection mix 
 DNA-Lipid complex  per well Lipofectamine® 3000 dilution 
Volume per well 
Culture 
vessel 
DNA 
(ng) 
P3000 
(µL) 
Opti-MEM 
(µL) 
Lipofectamine® 
3000 (µL) 
Opti-MEM 
(µL) 
Volume (Media) 
(µL) 
Volume (Transfection mix) 
(µL) 
6-well 2500  5 125 7.5 125 1750 250 
96-well 100 0.2 5 0.3 5 90 10 
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5.2.3 Immunocytochemistry 
 
PBS was made by dissolving 1 PBS tablet (Thermo Scientific, CA, USA) in 500 mL of dH2O. 
This solution was autoclaved at 121°C and 1 kg/cm2 for 20 minutes, cooled and stored at 
room temperature. 
Four percent paraformaldehyde (PFA) was made by adding 4 g of PFA into 80 mL of 1× 
PBS. This solution was incubated at 60 °C and 1 M NaOH was added drop-wise until solution 
was clear. The solution was cooled for 30 minutes at room temperature and the pH was 
adjusted to 6.9 and the volume adjusted to 100 mL with 1× PBS. This was filter sterilised and 
stored at -20 °C. 
Triton X (0.1 %) (Sigma-Aldrich, MO, USA) was made by adding 10 µL of Triton X to 10 
mL of 1× PBS. 
BSA (1%) (Roche Applied Science, Mannheim, Germany) was made by adding 0.1 g of BSA 
to 10 mL of 1× PBS. 
DAPI was made by dissolving 1 mg of DAPI into 1 mL of dH2O. This was filter sterilised and 
1× DAPI was made by diluting 1:1000 in 1× PBS 
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5.2.4 Immunofluorescence images from Huh7 cells 
 
 
Figure 5.7: GFP visualisation in transiently transfected Huh7 cells from the enzyme-
linked immunosorbent assay. 
Fluorescence microscopy was used to assess transfection efficiency for the ELISA. Huh7 cells were 
co-transfected with300 ng of pCH-9/3091, 200 ng of pCI-neo eGFP and 1000 ng of the left and right 
TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or 2000 ng of pUC118. Cells 
were imaged 48 hours after transfection. Representative images of pUC118, CWT, C Variant, SWT 
and S Variant are shown. 
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5.2.5 Immunofluorescence images from HepG2.2.15 cells 
 
 
Figure 5.8: Transient co-transfections in HepG2.2.15 cells. 
Fluorescence microscopy was used to assess transfection efficiency for the celI assay. HepG2.2.15 
cells were co-transfected with 200 ng of pCI-neo eGFP and 1000 ng of the left and right TALEN 
plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or 2000 ng of pUC118.Cells were 
imaged 48 hours after transfection. Images are from the first, second and third transfections. 
Representative images of pUC118, CWT, C Variant, SWT and S Variant from each transfection are 
shown. 
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5.2.6 PCR carried out on samples from HepG2.2.15 cells 
 
 
Figure 5.9: Agarose gel electrophoresis of PCR products obtained from treated 
HepG2.2.15 cells. 
HepG2.2.15 cells were transfected with pCMV C TALENs (WT), pCMV C TALENs (Var), pCMV S 
TALENs (WT), and pCMV S TALENs (Var) plasmids as well as pUC118 as a negative control. Total 
DNA was extracted from treated cells. The sequences spanning predicted target sites for the C (a) and 
S (b) TALENs were amplified by PCR. Three PCR products per TALEN treatment represents the 
triplicate transfection. Only the C target was amplified from DNA of cells treated with the C TALENs 
whereas only the S target was amplified from DNA of cells treated with the S TALENs. (c) The C 
(core) and S (Surface) target was amplified from DNA of cells treated with pUC118.(d)Wildtype (wt) 
and mutant (mt) HBx PCR amplicons mixed in a 1:1 ratio served as the positive control. This 
generated amplicons of 500 bp. (MWM: molecular weight marker, O’GeneRuler 1 kb DNA Ladder, 
Thermo Scientific, CA, USA). 
 
 
 
 
 
 
 
Chapter 5-Appendix 
100 
 
5.2.7 CelI assay carried out on PCR products from HepG2.2.15 cells 
 
 
Figure 5.10: TALEN-induced site-directed targeted mutagenesis in HepG2.2.15 cells. 
One microlitre of dH2O was added to each PCR product for the CWT and C Var controls (a) as well as 
for the SWT and S Var controls (b). Wildtype and mutant HBx PCR amplicons mixed in a 1:1 ratio 
served as the positive control (+) whereas PCR amplicons from pUC118-treated cells was used as a 
negative control (-). (MWM: molecular weight marker, O’GeneRuler 1 kb DNA Ladder, Thermo 
Scientific, CA, USA). 
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5.2.8 CelI targeted disruption calculation 
 
Image J (Freely available from http://imagej.net/Welcome) was used to measure band 
intensities from targeted disruption. This was achieved by measuring intensities of a defined 
area (fraction). 
The following equation was used to calculate targeted disruption:  
100 × (1 − (1 −
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑
𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑+𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑢𝑛𝑐𝑙𝑒𝑎𝑣𝑒𝑑
)0.5) 
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5.2.9 Immunofluorescence images from HEK293 cells 
 
 
Figure 5.11: GFP efficiency in transiently transfected HEK293 cells from the cell 
viability assay. 
Fluorescence microscopy was used to assess transfection efficiency for the cell viability assay. 
HEK293 cells were co-transfected with 15 ng of pCH-9/3091, 15 ng of pCI-neo eGFP and 85 ng of 
the left and right TALEN plasmids [either pCMV TALEN (WT) or pCMV TALEN (Var)] or 170 ng 
of pUC118. Cells were imaged 48 hours post transfection. Representative images of pUC118, CWT, C 
Variant, SWT and S Variant transfected cells are shown. 
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5.3 In vivo experiments 
5.3.1 Ethics certificate 
 
*The applicant, Miss P. Singh, applied for the ethics clearance certificate for a total of 60 
mice; this included the mice I required. I was a co-applicant with Miss Singh. My name does 
appear under Section A, 2.a of the application (See next page).  
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5.3.2 Endotoxin-free large scale plasmid preparation 
 
Material required 
o Endo-Free Plasmid Maxi kit (Qiagen, Hilden, Germany) 
o Bacterial culture 
Procedure 
Bulk endotoxin plasmid preparation was carried out similarly to the procedure described in 
5.10.7. Transformation and colony selection were performed as described in 5.10.3 and 
5.10.7. Pellets were harvested from 200 mL bacterial culture by centrifuging at 6000 ×g for 
30 minutes at 4 °C. The supernatant was discarded and the pellet was resuspended in 10 mL 
of buffer P1. Ten millilitres of buffer P2 was then added to the resuspensions and vigorously 
inverted followed by a five minute incubation at room temperature. Ten millilitres of buffer 
P3 was added and mixed by vigorous inversion. This lysate was poured into the barrel of the 
QIAfilter Cartridge and incubated at room temperature for 10 minutes. After the incubation, 
2.5 mL of buffer ER was added to the lysate. The lysate was then filtered into a clean 50 mL 
tube and left to incubate on ice for 30 minutes. During this incubation, 10 mL of buffer QBT 
was added to a QIAGEN-tip 500 column to equilibrate it. The supernatant was then left to 
enter the resin of the column by gravity flow. Once the supernatant completely passed through 
the column, 30 mL of endo-free buffer QC was added to the column, and allowed to drain by 
gravity flow. The wash step was repeated a second time. The DNA was eluted into a clean 50 
mL tube with 15 mL of QN buffer. DNA was precipitated by adding 10.5 mL of isopropanol 
to the eluted DNA, mixed and centrifuged at 15 000 ×g for 40 minutes at 4 °C. The 
supernatant was discarded, the pellet was washed in 5 mL of Endo-free 70% ethanol and 
centrifuged at 15 000 ×g for 20 minutes at 4 °C. The supernatant was carefully discarded and 
the pellet was air dried for 10 minutes. The pellet was then dissolved in 100 µL of Endo-free 
buffer TE. The purity and concentration of DNA was determined by spectrophotometry. The 
DNA was stored at -20 °C 
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5.3.3 PCR carried out on samples from murine hepatocytes 
 
 
Figure 5.12: Agarose gel electrophoresis of PCR products obtained from NMRI mice. 
NMRI mice were injected with pCMV C TALENs (WT), pCMV C TALENs (Var), pCMV S 
TALENs (WT), and pCMV S TALENs (Var) plasmids as well as pUC118 as a negative control. Total 
DNA was extracted from murine hepatocytes. The sequences spanning predicted target sites for the C 
WT (a), C Var (b), S WT (c) and S Var (d) TALENs were amplified by PCR. Each PCR product was 
from a different murine sample. Only the C target was amplified from DNA of cells treated with the C 
TALENs whereas only the S target was amplified from DNA of cells treated with the S TALENs. 
(e)The C (Core) and S (Surface) target was amplified from murine hepatocytes treated with pUC118. 
This generated amplicons of 500 bp. (MWM: molecular weight marker, O’GeneRuler 1 kb DNA 
Ladder, Thermo Scientific, CA, USA). 
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5.3.4 CelI assay carried out on PCR products from murine hepatocytes 
 
 
Figure 5.13: TALEN-induced site-directed targeted mutagenesis in murine hepatocytes. 
One microlitre of dH2O was added to each PCR product for the C WT (a), C Var (b), SWT (c) and S 
Var (d) controls. Wildtype and mutant HBx PCR amplicons mixed in a 1:1 ratio served as the positive 
control (+) whereas PCR amplicons from pUC118-treated mice was used as a negative control (-). 
(MWM: molecular weight marker, O’GeneRuler 1 kb DNA Ladder, Thermo Scientific, CA, USA). 
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